

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**Consolidated Financial Statements
for the year ended 31 December 2009
and
Independent Auditors' Report**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Consolidated Financial Statements
for the year ended 31 December 2009 and
Independent Auditors' Report

TABLE OF CONTENTS

| | <u>Page</u> |
|--|-------------|
| Independent Auditors' Report | - |
| Consolidated Statements of Financial Position as of 31 December 2009 and 2008 | 1 - 2 |
| Consolidated Statements of Comprehensive Income for the years ended 31 December 2009 and 2008 | 3 |
| Consolidated Statements of Changes in Equity for the years ended 31 December 2009 and 2008 | 4 |
| Consolidated Statements of Cash Flows for the years ended 31 December 2009 and 2008 | 5 |
| Notes to the Consolidated Financial Statements | 6 - 66 |

INDEPENDENT AUDITORS' REPORT

To the Board of Directors and Shareholders
Aksa Akrilik Kimya Sanayii A.Ş.

Introduction

We have audited the accompanying consolidated financial statements of Aksa Akrilik Kimya Sanayii A.Ş. (the Parent Company) and its Subsidiaries which comprise the consolidated statement of financial position as at December 31, 2009, and the consolidated statement of comprehensive income, the consolidated statement of changes in equity, and the consolidated statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Turkish Accounting / Financial Reporting Standards (TAS / TFRS) which are issued by the Turkish Accounting Standards Board (TASB) and which are similar to the International Accounting / Financial Reporting Standards (IAS / IFRS). This responsibility includes: designing, implementing and maintaining internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with the independent auditing standards issued by the Capital Markets Board. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the consolidated financial statements are free from material misstatement.

Our independent audit involves the application of independent auditing techniques to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The selection of the independent auditing techniques including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, is made by our professional judgment. In making those risk assessments; the internal control system of the entity is taken into consideration. However, this is not for the purpose of expressing an opinion on the effectiveness of the entity's internal control but for displaying the relationship between the consolidated financial statements and the internal control system prepared by the entity in order to design audit procedures that are appropriate in the circumstances. Our audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the accompanying consolidated financial statements give a true and fair view of the consolidated financial position of Aksa Akırlık Kimya Sanayii A.Ş. (the Parent Company) and its subsidiaries as of 31 December 2009, and of their consolidated financial performance and consolidated cash flows for the year then ended in accordance with the TAS/TFRS issued by the TASB.

Without qualifying our opinion, we draw attention to the following matter

As of 31 December 2009, the financial statements of the subsidiaries Fitco BV, Aksa Egypt Acrylic Fiber Industry S.A.E., and Akgirişim Kimya ve Ticaret A.Ş in which the Parent Company has a direct 100%, an indirect 99,14%, and a direct 58% interest, respectively, do not materially affect the consolidated financial statements, hence the subsidiaries referred to above are stated in the accompanying consolidated financial statements at cost.

İstanbul,
8 March 2010

Denet Bağımsız Denetim
Yeminli Mali Müşavirlik A.Ş.
Member firm of BDO International

Ömür Günel
Partner in charge

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Consolidated Statements of Financial Position
as of 31 December 2009 and 2008
(TL)

| | Notes | 31 December 2009 | 31 December 2008 |
|--|--------|----------------------|----------------------|
| ASSETS | | | |
| Current Assets | | 633,340,201 | 609,076,143 |
| Cash and Cash Equivalents | 2.4 | 112,113,221 | 63,583,555 |
| Trade Receivables | | | |
| - Other Trade Receivables | 2.7 | 321,609,682 | 358,870,759 |
| - Trade Receivables from Related Parties | 2,7,25 | 6,581,405 | 25,227,694 |
| Other Receivables | 8 | 42,832,366 | 45,348,215 |
| Inventories | 2.9 | 114,070,403 | 98,778,945 |
| Other Current Assets | 15 | 36,133,124 | 17,266,975 |
| Non-current Assets | | 645,607,606 | 519,407,632 |
| Trade Receivables | 2.7 | 11,732,305 | 12,665,408 |
| Other Receivables | 8 | 16,478 | 9,417 |
| Financial Assets | 2.5 | 7,999,781 | 7,999,781 |
| Tangible Assets | 2.10 | 559,130,427 | 454,539,216 |
| Intangible Assets | 2.11 | 9,372,526 | 3,025,618 |
| Goodwill | 2.12 | 5,988,651 | 5,988,651 |
| Other Non-current Assets | 15 | 51,367,438 | 35,179,541 |
| TOTAL ASSETS | | 1,278,947,807 | 1,128,483,775 |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Consolidated Statements of Financial Position
as of 31 December 2009 and 2008
(TL)

| | Notes | 31 December 2009 | 31 December 2008 |
|--|--------|----------------------|----------------------|
| LIABILITIES | | | |
| Short Term Liabilities | | 345,722,208 | 266,651,181 |
| Financial Liabilities | 2.6 | 141,840,558 | 118,482,414 |
| Trade Payables | | | |
| - Other Trade Payables | 2.7 | 156,258,378 | 94,170,237 |
| - Trade Payables to Related Parties | 2,7,25 | 12,905,084 | 16,946,866 |
| Other Liabilities | 8 | 4,736,770 | 3,293,370 |
| | 2,13,2 | | |
| Taxes on Profit for the Period | 3 | 1,221,503 | 8,103,146 |
| Debt Provisions | 2.13 | 2,113,495 | 3,800,167 |
| Other Short Term Liabilities | 15 | 26,646,420 | 21,854,981 |
| Long Term Liabilities | | 169,595,519 | 148,622,441 |
| Financial Liabilities | 2.6 | 137,400,143 | 121,089,861 |
| Trade Payables | 2,7,25 | 2,555,492 | - |
| Provision related to | | | |
| Employee Benefits | 2.14 | 11,520,027 | 9,354,382 |
| Deferred Tax Liability | 2.23 | 18,119,857 | 18,178,198 |
| EQUITY | | 763,630,080 | 713,210,153 |
| Parent Company Equity | | 749,041,143 | 698,351,826 |
| Share Capital | 16 | 185,000,000 | 110,000,000 |
| Capital Adjustment Differences | 16 | 195,174,673 | 255,174,673 |
| Issue Premiums | | 43,606 | 43,606 |
| Restricted Profit Reserves | 16 | 45,866,210 | 42,776,591 |
| Retained Earnings / (Accumulated Losses) | 16 | 272,267,337 | 217,449,747 |
| Net Profit/(Loss) For The Period | | 50,689,317 | 72,907,209 |
| Non-Controlling Interests | 2.16 | 14,588,937 | 14,858,327 |
| TOTAL LIABILITIES AND EQUITY | | 1,278,947,807 | 1,128,483,775 |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.
Consolidated Statements of Comprehensive Income
for the years ended 31 December 2009 and 2008
(TL)

| | Notes | 31 December 2009 | 31 December 2008 |
|--|---------|----------------------|----------------------|
| CONTINUING OPERATIONS | | | |
| Sales Income | 17 | 950,171,096 | 908,464,727 |
| Cost of Sales (-) | 17 | <u>(775,693,257)</u> | <u>(827,159,341)</u> |
| GROSS PROFIT / (LOSS) | | 174,477,839 | 81,305,386 |
| Marketing, Sales and Distribution Expenses (-) | 18 | (10,415,877) | (1,854,349) |
| General Administration Expenses (-) | 18 | (70,071,619) | (39,273,576) |
| Research and Development Expenses (-) | 18 | (9,352,919) | (9,180,410) |
| Other Operating Income | 20 | 19,373,246 | 14,376,271 |
| Other Operating Expenses (-) | 20 | <u>(36,379,755)</u> | <u>(4,110,399)</u> |
| OPERATING PROFIT / (LOSS) | | 67,630,915 | 41,262,923 |
| Financial Income | 21 | 127,226,815 | 152,326,373 |
| Financial Expenses (-) | 22 | <u>(130,583,595)</u> | <u>(101,706,930)</u> |
| CONTINUING OPERATIONS | | | |
| PROFIT/(LOSS) BEFORE TAX | | 64,274,135 | 91,882,366 |
| Current Period Tax Income/(Expense) | 2,13,23 | (11,282,887) | (15,750,109) |
| Deferred Tax Income/(Expense) | 2.23 | <u>58,340</u> | <u>(915,847)</u> |
| Continuing Operations Tax Income / (Expense) | 2.23 | <u>(11,224,547)</u> | <u>(16,665,956)</u> |
| CONTINUING OPERATIONS | | | |
| PROFIT/(LOSS) FOR THE PERIOD | | 53,049,588 | 75,216,410 |
| PROFIT/(LOSS) FOR THE PERIOD | | 53,049,588 | 75,216,410 |
| OTHER COMPREHENSIVE PROFIT/(LOSS) | | - | - |
| TOTAL COMPREHENSIVE PROFIT/(LOSS) | | 53,049,588 | 75,216,410 |
| Distribution of Profit/(Loss) for the Period | | | |
| Non-Controlling Interests | | 2,360,271 | 2,309,201 |
| Parent Company Shares | | 50,689,317 | 72,907,209 |
| Distribution of Total Comprehensive Profit/(Loss) | | | |
| Non-Controlling Interests | | 2,360,271 | 2,309,201 |
| Parent Company Shares | | 50,689,317 | 72,907,209 |
| Parent Company | | | |
| Earnings/ (Loss) per Share | 2.24 | 0.27 | 0.66 |
| Parent Company | | | |
| Diluted Earnings/ (Loss) per Share | 2.24 | 0.27 | 0.39 |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Consolidated Statements of Changes in Equity
for the years ended 31 December 2009 and 2008
(TL)

| | Notes | Share Capital | Share Capital Inflation Adjustment Differences | Issue Premiums | Restricted Profit Reserves | Retained Earnings/ (Accumulated Losses) | Net Profit/ (Loss) for the Period | Parent Company Equity | Non-Controlling Interest | Total |
|-----------------------------|-------|---------------|--|-------------------|----------------------------------|---|---|--------------------------|-----------------------------|-------------|
| Balance as at | | | | | | | | | | |
| 1 January 2008 | 16 | 110,000,000 | 255,174,673 | 43,606 | 16,579,576 | 238,916,635 | 4,730,127 | 625,444,617 | 15,755,617 | 641,200,234 |
| Transfer | 16 | - | - | - | - | 4,730,127 | (4,730,127) | - | - | - |
| Dividends paid | 16 | - | - | - | - | - | - | - | (3,206,491) | (3,206,491) |
| Gain on sale of investments | | - | - | - | 26,197,015 | (26,197,015) | - | - | - | - |
| Net profit for the period | 24 | - | - | - | - | - | 72,907,209 | 72,907,209 | 2,309,201 | 75,216,410 |
| Balance as at | | | | | | | | | | |
| 31 December 2008 | 16 | 110,000,000 | 255,174,673 | 43,606 | 42,776,591 | 217,449,747 | 72,907,209 | 698,351,826 | 14,858,327 | 713,210,153 |
| Capital increase | 16 | 75,000,000 | (60,000,000) | - | - | (15,000,000) | - | - | - | - |
| Transfer | 16 | - | - | - | - | 72,907,209 | (72,907,209) | - | - | - |
| Transfer to reserves | 16 | - | - | - | 2,969,994 | (2,969,994) | - | - | - | - |
| Dividends paid | 16 | - | - | - | - | - | - | - | (2,629,661) | (2,629,661) |
| Gain on sale of investments | | - | - | - | 119,625 | (119,625) | - | - | - | - |
| Net profit for the period | 24 | - | - | - | - | - | 50,689,317 | 50,689,317 | 2,360,271 | 53,049,588 |
| Balance as at | | | | | | | | | | |
| 31 December 2009 | | 185,000,000 | 195,174,673 | 43,606 | 45,866,210 | 272,267,337 | 50,689,317 | 749,041,143 | 14,588,937 | 763,630,080 |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Consolidated Statements of Cash Flows
for the years ended 31 December 2009 and 2008
(TL)

| | Notes | 31 December 2009 | 31 December 2008 |
|--|-------|----------------------|----------------------|
| A. CASH FLOWS FROM OPERATING ACTIVITIES | | | |
| Net profit (+) / loss (-) before tax | | 64,274,135 | 91,882,366 |
| <i>Adjustments:</i> | | | |
| Depreciation (+) | 19 | 50,720,829 | 37,664,885 |
| Provisions related to employee benefits | 13.14 | 2,165,645 | (6,309) |
| Inventory provision | 9 | 4,228,052 | 2,698,447 |
| Debt provisions | 13 | (1,686,672) | (183,892) |
| Rediscount income, net | 21.22 | (1,557,217) | (620,849) |
| Provision for doubtful trade receivables, net | 7 | 24,028,183 | 835,228 |
| Income from marketables securities or long term investments (-) | 21 | (3,631,798) | (3,979,573) |
| (Profit) / loss on sales of fixed assets | 20 | 102,022 | (226,204) |
| Profit on sales of financial assets | | - | (335,718) |
| Interest expense (+) | | 4,703,528 | 4,610,072 |
| Income Before Working Capital Changes (-) | | 143,346,707 | 132,338,453 |
| Increase (-) / decrease (+) in trade receivables | 7 | 34,984,006 | (114,209,801) |
| Increase (-) / decrease (+) in inventories | 9 | (18,105,703) | 22,430,172 |
| Increase (-) / decrease (+) in other receivables | 8 | 2,508,788 | (9,530,779) |
| Increase (-) / decrease (+) in other assets | 15 | (18,866,149) | 10,675,089 |
| Increase (+) / decrease (-) in trade payables | 7 | 59,987,348 | (14,930,157) |
| Increase (+) / decrease (-) in other payables | 8 | 1,443,400 | 356,072 |
| Increase (+) / decrease (-) in other liabilities | 15 | 4,791,439 | 12,609,915 |
| Interest payments (-) | | (3,435,845) | (2,853,931) |
| Tax payments (-) | 13 | (18,164,530) | (8,027,430) |
| Net cash provided from operating activities | | 188,489,461 | 28,857,603 |
| B. CASH FLOWS FROM INVESTING ACTIVITIES | | | |
| Financial assets sale total | | - | 399,300 |
| Tangible asset acquisition (-) | 10 | (157,535,406) | (129,855,903) |
| Intangible asset acquisition (-) | 11 | (6,503,299) | (262,590) |
| Cash inflows from disposal of tangible and intangible assets(+) | 10.11 | 863,927 | 1,421,147 |
| Increase (-) / decrease (+) in other non-current assets | 15 | (16,187,897) | (33,418,018) |
| Collected interests (+) | 21 | 3,631,798 | 3,979,573 |
| Net cash (used in) investing activities | | (175,730,877) | (157,736,491) |
| C. CASH FLOWS FROM FINANCING ACTIVITIES | | | |
| Cash inflows / (outflows) related to short and long term liabilities | 6 | 38,400,743 | 135,995,134 |
| Effect of change in non-controlling interest | | (2,629,661) | (3,206,491) |
| Net cash provided from financing activities | | 35,771,082 | 132,788,643 |
| Increase/(decrease) in cash and cash equivalents | | 48,529,666 | 3,909,755 |
| Cash and cash equivalents at the beginning of the period | 2.4 | 63,583,555 | 59,673,800 |
| Cash and cash equivalents at the end of the period | 2.4 | 112,113,221 | 63,583,555 |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

1. Organization and Principal Activities

Aksa Akriklik Kimya Sanayii A.Ş. (the Parent Company) is a company incorporated in Istanbul whose principal activities are the production of acrylic based tow, fiber, tops and electricity. Its subsidiaries mainly operate in textiles, chemistry, investment, and service sectors. The Parent Company's subsidiaries comprise of the following companies:

| <u>Parent Company:</u> | <u>Sector</u> |
|---|----------------------|
| Aksa Akriklik Kimya Sanayii A.Ş. - Turkey | Chemistry and Energy |

Subsidiaries:

| | |
|--|------------|
| Ak-Pa Tekstil İhracat Pazarlama A.Ş. - Turkey * | Marketing |
| Ak-Tops Tekstil Sanayi A.Ş. - Turkey * | Textile |
| Fitco BV - the Netherlands ** | Investment |
| Aksa Egypt Acrylic Fiber Industry SAE - Egypt ** | Textile |
| Akgirişim Kimya ve Ticaret A.Ş. - Turkey ** | Chemistry |

* Included in the consolidated financial statements in accordance with the full consolidation method.

** Stated in the consolidated financial statements at cost.

Aksa Egypt Acrylic Fiber Industry SAE is an indirect subsidiary of the Parent Company in which Fitco BV, Ak-Pa Tekstil İhracat Pazarlama A.Ş., and Ak-Tops Tekstil Sanayi A.Ş. have interests of 99%, 0,5%, and 0,5%, respectively.

The address of the Parent Company's head office is as follows:
Miralay Şefik Bey Sok. No: 15 Akhan 34437 Gümüşsuyu/İstanbul - Turkey

The Parent Company is registered at the Capital Markets Board and 37,92 % of its shares are traded at the Istanbul Stock Exchange (ISE).

As of 31 December 2009 and 2008, the shareholding structure of the Parent Company is as follows:

| <u>Name</u> | <u>31 December 2009 Shareholding</u> | <u>31 December 2008 Shareholding</u> |
|---|--|--|
| Akkök Sanayi Yatırım ve Geliştirme A.Ş. | 39,58% | 39,58% |
| Emniyet Tic. ve San. A.Ş. | 18,72% | 18,72% |
| Other* | 41,70% | 41,70% |
| | <u>100,00%</u> | <u>100,00%</u> |

* Represents shareholdings of less than 10%.

As of 31 December 2009, the average number of employees is 1.116 (31 December 2008 - 902).

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements

i. Basis of Presentation:

The Parent Company and its subsidiaries maintain their books of account and prepare their statutory financial statements in accordance with the prevailing commercial and financial legislation. The accompanying consolidated financial statements are prepared in accordance with the Capital Markets Board (CMB) Communiqué Nr. XI/29 “Communiqué Related to the Financial Reporting Principles at the Capital Markets”. This Communiqué has come into force starting with the first interim consolidated financial statements subsequent to 1 January 2008 and bears in its Article 5 the provision stating that the enterprises subject to CMB apply the International Accounting / Financial Reporting Standards as accepted by the European Union (EU) taking as basis the harmonic standards, namely the Turkish Accounting / Financial Reporting Standards (TAS/TFRS), issued by the Turkish Accounting Standards Board (TASB). Furthermore, in the provisional Article 2 of the same Communiqué it is stated that the IAS/IFRS are to be applied taking as basis the harmonic standards, TAS/TFRS, issued by the TASB until the differences between the IAS/IFRS accepted by the European Union and those issued by the International Accounting Standards Board (IASB) are published by the TASB.

However, the Turkish Accounting Standards Board (“TASB”) has not issued the differences between the IAS/IFRS accepted by the EU and the standards issued by the International Accounting Standards Board (“IASB”) to date; hence, the accompanying consolidated financial statements are prepared in accordance with the IAS/IFRS taking as basis the harmonic standards TAS/TFRS issued by the TASB. As required by the TFRS 1, comparative financial statements are prepared on the same basis. As stated below, certain adjustments and classifications have been made during the preparation of the accompanying financial statements in order to comply with the TAS/TFRS.

The accompanying consolidated financial statements and explanatory notes are presented in accordance with the mandatory formats and principles announced by CMB in its Weekly Bulletin dated 14-18 April 2008 Nr. 2008/16. In line with the revisions in TAS1 which is valid for the financial periods starting on or subsequent to 1 January 2009, the balance sheet is presented under the name of the statement of financial position, and the profit/loss sections are presented under a single statement of comprehensive income.

As per the resolution of the Council of Ministers dated 4 April 2007 Nr. 2007/11963, the word “New” in the “New Turkish Lira” and in the “New Kuruş” have been cancelled with effect from 1 January 2009. Accordingly, TRY 1 (New Turkish Lira) will be equal to TL 1 (Turkish Lira).

The functional currency used by the Parent Company and its subsidiaries is Turkish Lira (TL) and the accompanying consolidated financial statements and related notes are presented in TL.

The Company’s consolidated financial statements prepared at 31 December 2009 in accordance with the Communiqué XI/29 are approved at 8 March 2010 by the Company management to be submitted to the Board of Directors.

The Board of Directors of the Parent Company and the CMB have the power to amend the interim financial statements, and the General Assembly and the CMB retain the right to amend the annual financial statements.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements (continued)

ii. Adjustment of Financial Statements During Hyper-Inflationary Periods:

TAS 29 deals with the effects of inflation on financial statements and requires that financial statements prepared in the currency of a high inflation economy be stated in terms of the measuring unit current at the reporting date and that corresponding figures for previous periods be restated in the same terms. As per the resolution of the CMB dated 17 March 2005 Nr 11/367 the application of inflation adjustment of the financial statements has ended in 2005, hence the financial statements are restated at the purchasing value of the Turkish Lira as at 31 December 2004. Additions to non-monetary items subsequent to 1 January 2005 are stated at their nominal values.

iii. Consolidation Principles:

Consolidation is realized within the Parent Company, Aksa Akrilik Kimya Sanayii A.Ş. and the direct and indirect shareholdings of the Parent Company within its subsidiaries are as follows :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| <u>Subsidiaries</u> | | |
| Ak-Pa Tekstil İhracat Pazarlama A.Ş. (1) | 13,47% | 13,47% |
| Ak-Tops Tekstil San. A.Ş. (1) | 60,00% | 60,00% |
| Fitco BV (2) | 100,00% | 100,00% |
| Aksa Egypt Acrylic Fiber Industry SAE (2)(3) | 99,14% | 99,14% |
| Akgirişim Kimya ve Ticaret A.Ş. (2) | 58,00% | 58,00% |

(1) Stated in the accompanying consolidated financial statements as per the full consolidation method.

(2) An indirect subsidiary stated in the accompanying consolidated financial statements at cost due to its immaterial effect.

(3) Indirect subsidiary.

Subsidiaries and affiliates are classified as financial assets available for sale representing shareholdings in which the direct and indirect votes of the Parent Company is below 20% or with insignificant influence even if above 20%, or those that do not have material effect on consolidated financial statements, or are not traded in the active markets or whose fair values cannot be determined reliably, are recognised at their restated cost values, less provision for value decrease, if any.

Consolidated financial statements have been prepared on the basis of principles stated below:

Full Consolidation Method:

- All items of the statement of financial position except for the paid in capital of the Parent Company and its subsidiaries and their equities at the acquisition date are added, and inter-company balances are eliminated.

2. Presentation of the Financial Statements (continued)

iii. Consolidation Principles (continued):

Full Consolidation Method (continued):

- The Parent Company's interest in the subsidiaries is set off against the Long Term Financial Assets account of the Parent Company and the Share Capital accounts of the subsidiaries.
- As of the acquisition date, the Parent Company's shareholding in its subsidiaries is set off against the portion of share capital it owns in the subsidiary's equity for one single time. The equity of the subsidiary at the acquisition date should be drawn up according to the market value of the subsidiary's net assets at that date. The difference that appears in favor of the recorded value is recognized as positive goodwill in the consolidated statement of financial position as a separate item and that which appears against the recorded value is recognized as negative goodwill in the statement of comprehensive income. The Parent Company has taken over at a total price of TL 16.250.000,00 the participation shares of TL 1.000.000 nominal value representing 50% of the share capital of Aktops Tekstil Sanayi A.Ş., a company under the ownership of Akkök Sanayi Yatırım ve Geliştirme A.Ş., with a share capital of TL 2.000.000 which is directly related to the Parent Company's principal activities and which makes exclusive custom manufacturing for the Parent Company and whose share transfer fee has been determined by the Valuation Report submitted by İş Yatırım Menkul Değerler A.Ş. as of 8 June 2007.
- As the cost of acquired subsidiary is higher than the value of shares stated among equities in the consolidated statements of financial position prepared in accordance with TAS/TFRS at the acquisition dates of the subsidiaries, a total positive goodwill of TL 5.988.651 has been created (Note 12). In the event of any value decrease related to the goodwill amount, it is reflected to the statement of comprehensive income. A value decrease test is performed at the same date of each year in order to determine if there is any value decrease in the goodwill. As of 31 December 2009 and 2008, there is no impairment in goodwill.
- The totals related to shares other than the Parent Company shares are deducted from all equity account group items including the paid in/issued share capital of subsidiaries included in the consolidation and are recognized as "Non-controlling Interests" in the consolidated statement of financial position and in the consolidated statement of comprehensive income as an item separated from the Parent Company's equity share.
- The purchase and sales among the Parent Company and its Subsidiaries and the profit and losses arising from these transactions are eliminated in the consolidated statement of comprehensive income. Profit and losses arising from the purchase or sale of marketable securities, inventories, tangible and intangible assets, long term financial assets and other assets among the consolidated group companies are also eliminated.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements (continued)

iv. Adjustments :

The accompanying consolidated financial statements have been prepared in accordance with the TAS/TFRS with the below mentioned adjustments which are not stated in the statutory records:

- Rediscount calculation on post-dated cheques, notes receivable, customers, notes payable, suppliers, and loans
- Depreciation adjustment
- Deferred tax adjustment
- Inventory provision adjustment
- Adjustment of provision for doubtful receivables
- Provision for litigation
- Adjustment related to investments in progress
- Adjustment of provision for termination indemnity
- Adjustment related to derivative financial instruments
- Adjustments related to cash and cash equivalents
- Expense accrual adjustment
- Elimination of inter-group balances and transactions as per the consolidation procedure

v. Comparative Information and Adjustment of Prior Period Financial Statements:

Consolidated statements of financial position as of 31 December 2009 and 2008 and notes to these statements as well as the consolidated statements of comprehensive income, changes in equity, and cash flows for the years then ended have been presented comparatively. In order to comply with the presentation of the current period financial statements, the comparative information is reclassified when deemed necessary. TL 3.800.769 of maturity difference and foreign exchange gains followed up under other operating income as of 31 December 2008 are classified under financial income.

vi. Offsetting:

Offsetting financial assets and liabilities can only be made under the conditions where the offsetting transaction is legally allowed and the company has an intention in this respect or where the acquisition of assets and fulfillment of liabilities are realized simultaneously.

vii. Accounting Policies, Changes and Errors in Accounting Estimates:

The accounting policies applied by the Parent Company and its subsidiaries are consistent with those applied in the prior year. Significant changes in accounting policies are applied and significant errors are treated, retrospectively, and the prior year financials are restated. Changes in accounting policies are applied in the period of the change if they are related to the one period only; however, if they are related to the future periods, they are applied both in the period of change and the future period, prospectively.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements (continued)

viii. The New and Revised Turkish Accounting / Financial Reporting Standards:

During the current period, TASB has issued the new and revised standards with effect from 1 January 2009 and 1 July 2009, and the Parent Company and its subsidiaries have applied those that relate to their own field of activity.

The standards, changes and comments that have come into force in 2009 but not applied by the Parent Company and its subsidiaries as they have no relation with the Parent Company and its subsidiaries operations:

The standards listed below and the changes and comments introduced to the prior standards have been enforced for the financial periods starting at or subsequent to 1 January 2009 and 1 July 2009. However, such standards, changes and comments are not related to the operations of the Parent Company and its subsidiaries; hence, they are not applied.

Changes to be applied for periods starting at or subsequent to 1 January 2009:

- TAS 16 - “Tangible Assets - Recoverable Value, Disposal of Assets Held for Leasing”
- TAS 19 - “Employee Benefits - Curtailments and Negative Past Service Cost, Plan Management Cost, Change of the term “Matured”, Guidelines to Contingent Liabilities”
- TAS 20 - “Accounting for Government Grants and Disclosure of Government Assistance - Government Loans at a Below-Market Rate of Interest”

Changes to be applied for periods starting at or subsequent to 1 July 2009;

- TFRS 1 - “First-Time Adoption of International Financial Reporting Standards”
- TFRS 3 - “Business Combinations”
- TAS 28 - “Investments in Associates”
- TAS 31 - “Interests in Joint Ventures”
- TFRS Comment 17 - “Distribution of Non-Cash Assets to Owners”

ix. Significant Accounting Policies and Valuation Procedures Applied:

(a) Financial Instruments:

Financial instruments consist of the financial assets and liabilities stated below:

i. Cash and Cash Equivalents

Cash and cash equivalents consist of cash balances on hand, bank accounts, cheques received, and other liquid assets.

Cash is composed of Turkish Lira and foreign currency balances. The Turkish Lira balances are stated at face values, and the foreign currency balances are translated into Turkish Lira at the foreign exchange rate issued by the Central Bank at the end of the reporting period.

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(a) Financial Instruments (continued):

i. Cash and Cash Equivalents (continued):

Bank accounts consist of demand and time deposit accounts and the related interest accrued. Turkish Lira deposit accounts are stated at cost and foreign currency accounts are translated into Turkish Lira at the foreign currency rate issued by the Central Bank at the end of the reporting period.

The cheques received with maturity dates exceeding the reporting date are stated in trade receivables and are rediscounted at a rate equivalent to the interest rate of government bonds constituted in stock markets or other organized markets.

Fair Value

As the foreign currency cash and cash equivalents are translated into Turkish Lira at the foreign exchange rates valid at the reporting date, it is assumed that the fair values of these assets approximate to their book values.

As the deposit accounts, cash and cheques received are converted into cash in very short terms, and as there is no risk of value decrease, their book values are deemed to approximate to their fair values.

ii. Trade Receivables

Trade receivables are financial assets created by the Parent Company and its subsidiaries through selling goods and services directly to the customers. Trade receivables and post dated cheques are subject to rediscount

Fair Value

Discounted trade receivables for which provisions are accrued are assumed to approximate to the fair values of these assets.

iii. Related Parties

A party is related to an entity if the party is a legal body or a real person which directly or indirectly controls, is controlled by, or is under common control with the entity, has an interest in the entity that gives it significant influence over the entity, and if the party is a subsidiary, an affiliate or a joint venture in which the entity is a venturer. Furthermore, members of the key management personnel of the entity, close members of the family of any individual referred to above, and parties representing post-employment benefit plan for the benefit of employees of the entity are also defined as related parties.

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(a) Financial Instruments (continued):

iv. Trade Payables

Trade payables are financial liabilities created through acquiring goods and services directly from the suppliers.

Fair Value

The discounted value of trade payables are assumed to approximate to their fair values.

v. Short and Long Term Bank Loans

Short and long term bank loans are stated at the value computed through addition of the principal amount and the interest expenses accrued as of the reporting date, discounted as per the effective interest method.

Fair Value

The fair value of the short and long term bank loans is assumed to be equivalent to the recorded values computed by adding the accrued interest liabilities calculated over the effective interest rate as of the reporting dates on the cost of the mentioned financial debts.

vi. Financial Derivative Instruments

The Parent Company enters into forward contracts and realizes interest rate swap operations with the objective to hedge against foreign currency risk and loan interest risk arising from its operating and financing activities. The current value of outstanding contracts is calculated by using internal pricing models and the unrealized foreign exchange gains/losses are recognized in the statement of comprehensive income.

(b) Inventories:

Inventories are stated at the lower of cost or net realisable value. Cost is determined by using the weighted average cost method.

Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Cost is determined by using the weighted average cost method covering a reasonable portion of raw material, supplies, labor and general production expenses.

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(c) Financial Assets :

The Parent Company has classified its financial investments as financial assets available for sale.

Financial assets available for sale consist of financial investments other than operating loans and receivables, and financial assets held until maturity and for trading purposes. Financial assets available for sale are valued at their fair value in the period following the initial recording. Financial assets available for sale in which the direct and indirect votes of the Parent Company is below 20% or with insignificant influence even if above 20%, or those that do not have material effect on financial statements, or are not traded in the active markets or whose fair values cannot be determined reliably, are recognised at their cost values, less provision for value decrease, if any. Financial investments do not have a market value and are recognized at their unit values restated as of 31 December 2004, less provision for value decrease, if any. Furthermore, the financial assets available for sale whose market values are quoted at active markets and can be determined reliably are recognized at their fair values.

(d) Tangible Assets:

Tangible assets are stated at cost less their accumulated depreciation and impairment loss, if any.

Tangible assets have been restated using the measuring unit current at 31 December 2004 from the dates of acquisition. Additions made subsequent to 1 January 2005 are stated at their nominal values. Depreciation of tangible assets is made over the inflation-adjusted amounts and the nominal values for the acquisitions subsequent to 1 January 2005 on a straight-line basis based on the estimated useful lives of these assets.

The depreciation periods which approximate to the economic useful lives of the assets are as follows:

| | |
|--------------------------------|------------|
| Buildings | 5-50 years |
| Land improvements | 2-50 years |
| Machinery, plant and equipment | 3-30 years |
| Motor vehicles | 4- 8 years |
| Furniture and fixtures | 2-50 years |
| Other tangible assets | 5 years |

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(e) Intangible Assets:

Intangible assets are stated at cost less their accumulated amortisation and impairment loss, if any.

The acquisition values of intangible assets are considered in the restatement of intangible assets as at 31 December 2004. Additions made subsequent to 1 January 2005 are stated at their nominal values. Intangible assets are amortized over their inflation-adjusted values and the nominal values of additions subsequent to 1 January 2005, as per their useful lives stated below :

| | |
|--|------------|
| Rights | 3-40 years |
| Intangible assets arising from development phase of an internal project | 5 years |
| Special costs | 1-5 years |
| Other intangible assets | 3-5 years |

(f) Intangible Assets Arising From Development Phase of an Internal Project :

Project costs related to new product development or testing and design of the newly developed products are recognized as intangible assets in the event that the project is successfully applied in terms of technology and trade and that the costs are determined reliably. Other development expenses and research expenses are recognized when they are realized. A development expense recognized in the prior period cannot be capitalized in the succeeding period.

The Parent Company deals with the production and trade of a carbon fiber project which is planned to be introduced to the market during the future periods. Intangible assets arising from the development phase of the said project are recognized under the Intangible Assets account group.

(g) Assets and Liabilities in Foreign Currency:

Foreign currency assets and liabilities recognized in the statement of financial position are translated into Turkish Lira at the foreign exchange rates announced by the Turkish Central Bank at the reporting dates. Transactions in foreign currencies during the period are translated into Turkish Lira at the actual rates applicable on the transaction date. Exchange gains and losses resulting from such translations are included in the statements of comprehensive income.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(h) Impairment of Assets:

In case the book value of an asset exceeds its recoverable value, a provision for impairment loss is made so as to bring the book value of the asset down to the level of its fair value and the provision is recorded in the statement of comprehensive income as expense.

On the other hand, the recoverable value of cash generating assets is the higher of the value computed by subtracting the sales value of the asset from its fair value compared to the value in use of the asset. The value in use of the said assets is the present value of the cash flows expected to be obtained from the assets. For the calculation of the value in use, the future cash flow estimates are discounted to their present value by using the time value of money and the discount rate before tax which reflects risks attributable to the asset.

(i) Deferred Taxes:

Deferred taxes are calculated on the temporary differences that arise between the deductible tax base and the book values of assets and liabilities, by using the liability method. The main temporary differences arise from the income and expense items recognised in different periods with respect to the TAS/TFRS and the tax legislation. While deferred tax liabilities are calculated for all taxable temporary differences, deferred tax assets consisting of deductible temporary differences are calculated with the assumption that the Parent Company and its Subsidiaries will have taxable income during the future periods.

An enterprise should offset current tax assets and current tax liabilities if the enterprise has a legally enforceable right to set off the recognised amounts, provided that the tax assets and tax liabilities are subject to the tax legislation of the same jurisdiction.

(j) Income Taxes:

Under the Turkish Tax Code, a company that has its head office or place of business in Turkey is subject to a corporate tax.

Under the Turkish taxation system, tax losses can be carried forward to be offset against future taxable income for up to five years. Tax losses cannot be carried back to offset profits from previous periods.

Corporate earnings are subject to corporation tax at a rate of 20%. Whether exempted or not, dividends paid in cash to real persons with full liability and real persons and entities with limited liability (non-residents) are subject to income tax withholding at a rate of 15%. However, income tax withholding is not applicable to the dividends arising from 1998 and prior years' profits and from the exempt profits relating to the years 1999, 2000, 2001 and 2002 as well as income and profits corresponding to the above mentioned investment allowance taxed at the rate of 19,8%. Addition of current year and prior year profits (retained earnings) to share capital has not been regarded as distribution of profits and therefore no withholding tax is applicable to these earnings. On the other hand, no withholding tax is applicable to entities with full liability in profit distributions.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(j) Income Taxes (continued):

Further, provisional corporation tax is paid at a rate of 20% on the profits declared for interim periods to be deducted from the corporation tax.

With respect to the article 298 (bis) of the Tax Law amended by Law 5024 to be enacted as of 1 January 2004, the financial statements of the tax payers whose earnings are determined on balance sheet basis are subject to inflation adjustment in the event that the increase in price indices exceed 100% for the last three accounting periods including the current period and 10% for the current accounting period. In the 2009 and 2008 accounting periods, the criteria of 100% and 10% have not been realized simultaneously in the Producers Price Index and for that reason no inflation adjustment has been applied.

As of 31 December 2009 and 2008 income tax provisions have been made in accordance with the prevailing tax legislation.

(k) Employee Benefits:

Under Turkish Labour Law Article 25/II, the Company is required to pay termination indemnities to each employee who completes one year of service and whose employment is terminated upon causes that qualify the employee to receive termination indemnity, is called up for military service, leaves within one year after marriage (women only), and to those employees who retire or die. The amount payable consists of one month's salary for each year of service. This entitlement is limited to TL 2.365,16 in respect of each year of service as of 31 December 2009 (31 December 2008 - TL 2.173,19).

The Company has determined the termination indemnity liability stated in the accompanying financial statements as per the recognition and valuation principles stated in TAS 19 "Employee Benefits". As the characteristics of the termination indemnity liabilities are similar to the "Post Employment Benefit Plans" stated in this standard, these liabilities are calculated and stated in the financial statements on the basis of below mentioned "Proposed Unit Loan Method" and other various assumptions.

- The dates that the employees will gain their pension rights are determined with respect to the prevailing social security laws with consideration to their past employment durations.
- In calculating the current value of future liabilities that may arise due to the retirement or contract termination of an employee, it is assumed that the current salaries and wages or the value of the termination indemnity upper limit determined by the Labour Law for 31 December 2009 to remain constant for restatement purposes, and later on, this value is reduced by the actual discount rate of 5,92% (31 December 2008 - 6,26%) calculated upon the assumption that the expected annual inflation rate will be 4,8% (31 December 2008 - 5,4%) and the expected discount rate will be 11% (31 December 2008 - 12%) which represents the proposed average interest rate per annum of the government bonds, in order to determine the current net value of the termination indemnity liability at the reporting date.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(k) Employee Benefits (continued):

As of 31 December 2009 and 2008, assumptions for calculating termination indemnity are as follows:

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Discount rate | 5,92 % | 6,26 % |
| The ratio of the number of employees who have gained the right to receive termination indemnity in the prior years to the total number of employees | 100 % | 100 % |

(l) Revenues and Expenses:

The accruals basis of accounting is applied for the recognition of revenues and expenses. The accrual concept requires that revenue, income and profits should be matched with costs, expenses and losses belonging to the same period.

Revenue from the sale of goods is recognized when the entity has transferred to the buyer the significant risks and rewards of ownership of the goods, when the entity retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold, when the amount of revenue can be measured reliably, when it is probable that the economic benefits associated with the transaction will flow to the entity, and when the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Interest revenue accrual is calculated over the effective interest rate. Leasing income/expenses originating from operational leasing are recognized in the financial statements as income/expense on straight line basis throughout the leasing period.

Dividend income is recognized at the time when collection right is established.

(m) Earnings/(Loss) Per Share:

Earnings / (loss) per share is calculated by dividing the net profit or loss for the period attributable to ordinary equity holders of the parent company by the weighted average number of ordinary shares outstanding during the period.

Companies in Turkey can increase their share capital through distributing shares (bonus shares) from retained earnings and differences arising from inflation adjustment in equity to their current shareholders on a pro rata basis. When calculating profit/(loss) per share, these bonus shares are recognized as issued shares. Therefore, the weighted average of shares used in the calculation of profit/(loss) per share is derived through retroactive application with respect to bonus shares.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

2. Presentation of the Financial Statements (continued)

ix. Significant Accounting Policies and Valuation Procedures Applied (continued):

(n) Accounting Estimates:

During the preparation of financial statements in accordance with the TAS/IFRS, the Management may make assumptions and estimates that might affect the book value of the assets and liabilities stated in the financial statements as of the end of the reporting period, explanations regarding unrecognized liabilities, and income and expense totals related to the period. However, actual results may vary from these results.

(o) Events After the Reporting Period:

The Parent Company and its subsidiaries should update disclosures that relate to conditions that existed at the end of the reporting period to reflect any new information that they receive after the reporting period about those conditions. Non-adjusting events should be disclosed if they are of such importance that non-disclosure would affect the ability of users to make proper evaluations and decisions.

(p) Conditional Assets and Liabilities:

Assets and liabilities that originate from past incidents and whose presence is not fully under the company management control as it can only be confirmed through the realization of one or more indefinite incidents to take place in the future are not included in the financial statements and are classified as conditional liabilities and assets.

(r) Borrowing Costs:

Borrowing costs are recognized as expense. Borrowing costs related to the qualifying assets are included directly in the cost of the related qualifying asset. Upon completion of the necessary operations to make the qualifying asset ready for use or sale, the capitalization of the borrowing costs are discontinued. As of 31 December 2009, the borrowing costs amounting to TL 1.683.972 directly related to the investments in progress are added to the cost of the related asset (31 December - TL 24.667.878)(Note 10).

(s) Segment Reporting:

For the years ended 31 December 2009 and 2008, the operating activities of the Parent Company and its Subsidiaries are classified under three sectors, namely, chemistry, textiles, and marketing.

(t) Government Incentives and Grants:

The government incentives utilized by the Parent Company are those that are related to revenues and they are recognized in the statement of comprehensive income.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

3. Segment Reporting

As of 31 December 2009, segment reporting consists of the following (TL):

| | Chemistry * | Textile | Marketing | Classification and Elimination | Total |
|----------------------------|-----------------------------|--------------------------|---------------------------|--------------------------------------|-----------------------------|
| ASSETS | | | | | |
| Current Assets | 603.975.240 | 11.399.928 | 115.105.287 | (97.140.254) | 633.340.201 |
| Cash and Cash Equivalents | 106.271.532 | 2.508.600 | 3.333.089 | - | 112.113.221 |
| Trade Receivables | | | | | |
| - Other Trade Receivables | 224.755.693 | 164.043 | 96.689.946 | - | 321.609.682 |
| - Due from Related Parties | 93.962.746 | 5.715.386 | 3.619.779 | (96.716.506) | 6.581.405 |
| Other Receivables | 32.523.140 | 769.473 | 9.539.753 | - | 42.832.366 |
| Inventories | 110.807.375 | 1.922.231 | 1.764.545 | (423.748) | 114.070.403 |
| Other Current Assets | 35.654.754 | 320.195 | 158.175 | - | 36.133.124 |
| Non-current Assets | 643.354.649 | 13.749.589 | 2.545.641 | (14.042.273) | 645.607.606 |
| Trade Receivables | 11.732.305 | - | - | - | 11.732.305 |
| Other Receivables | 11.547 | 4.931 | - | - | 16.478 |
| Financial Assets | 27.138.270 | 39.361 | 39.388 | (19.217.238) | 7.999.781 |
| Tangible Assets | 546.376.998 | 11.065.073 | 2.502.042 | (813.686) | 559.130.427 |
| Intangible Assets | 6.728.091 | 2.640.224 | 4.211 | - | 9.372.526 |
| Goodwill | - | - | - | 5.988.651 | 5.988.651 |
| Other Non-current Assets | <u>51.367.438</u> | <u>-</u> | <u>-</u> | <u>-</u> | <u>51.367.438</u> |
| TOTAL ASSETS | <u>1.247.329.889</u> | <u>25.149.517</u> | <u>117.650.928</u> | <u>(111.182.527)</u> | <u>1.278.947.807</u> |

* Chemistry sector includes the financial data related to the Parent Company.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

3. Segment Reporting

As of 31 December 2009, segment reporting consists of the following (TL) (continued):

| | Chemistry * | Textile | Marketing | Classification and Elimination | Total |
|---|-----------------------------|--------------------------|---------------------------|--------------------------------------|-----------------------------|
| LIABILITIES | | | | | |
| Short Term Liabilities | 330.159.956 | 2.278.159 | 110.045.628 | (96.761.535) | 345.722.208 |
| Financial Debts | 132.285.150 | 2.194 | 9.553.214 | - | 141.840.558 |
| Trade Payables | | | | | |
| - Other Trade Payables | 152.364.938 | 409.086 | 3.484.354 | - | 156.258.378 |
| - Due to Related Parties | 13.042.574 | 387.411 | 96.236.634 | (96.761.535) | 12.905.084 |
| Other Payables | 3.965.197 | 250.744 | 520.829 | - | 4.736.770 |
| Taxes Payable on Profit for the Current Period | 523.319 | 447.587 | 250.597 | - | 1.221.503 |
| Debt Provisions | 1.463.029 | 650.466 | - | - | 2.113.495 |
| Other Short Term Liabilities | 26.515.749 | 130.671 | - | - | 26.646.420 |
| Long Term Liabilities | 167.254.041 | 2.105.292 | 311.926 | (75.740) | 169.595.519 |
| Financial Debts | 137.400.143 | - | - | - | 137.400.143 |
| Trade Payables | 2.555.492 | - | - | - | 2.555.492 |
| Provision for | | | | | |
| Employee Benefits | 9.495.556 | 1.612.309 | 412.162 | - | 11.520.027 |
| Deferred Tax Liability | 17.802.850 | 492.983 | (100.236) | (75.740) | 18.119.857 |
| EQUITY | 749.915.892 | 20.766.066 | 7.293.374 | (14.345.252) | 763.630.080 |
| Parent Company Equity | 749.915.892 | 20.766.066 | 7.293.374 | (28.934.189) | 749.041.143 |
| Paid-in Capital | 380.174.674 | 8.465.590 | 17.440.373 | (221.080.637) | 185.000.000 |
| Inflation Adjustment on Share Capital | - | - | - | 195.174.673 | 195.174.673 |
| Issue Premiums | 1.669.549 | - | - | (1.625.943) | 43.606 |
| Restricted Profit Reserves | 122.307.449 | 10.616.750 | 1.441.257 | (88.499.246) | 45.866.210 |
| Retained Earnings / (Accumulated Losses) | 194.195.132 | (729.620) | (13.200.336) | 92.002.161 | 272.267.337 |
| Net Profit / (Loss) for the Period | 51.569.088 | 2.413.346 | 1.612.080 | (4.905.197) | 50.689.317 |
| Non-controlling Interests | - | - | - | <u>14.588.937</u> | <u>14.588.937</u> |
| TOTAL LIABILITIES AND EQUITY | <u>1.247.329.889</u> | <u>25.149.517</u> | <u>117.650.928</u> | <u>(111.182.527)</u> | <u>1.278.947.807</u> |

* Chemistry sector includes the financial data related to the Parent Company.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

3. Segment Reporting

As of 31 December 2009, segment reporting consists of the following (TL) (continued):

| | Chemistry * | Textile | Marketing | Classification and Elimination | Total |
|--|----------------------|---------------------|----------------------|--------------------------------------|----------------------|
| CONTINUING ACTIVITIES | | | | | |
| Sales Income (net) | 906.377.578 | 30.393.554 | 422.891.008 | (409.491.044) | 950.171.096 |
| Cost of Sales (-) | <u>(747.678.561)</u> | <u>(23.861.375)</u> | <u>(416.653.517)</u> | <u>412.500.196</u> | <u>(775.693.257)</u> |
| GROSS PROFIT/(LOSS) | 158.699.017 | 6.532.179 | 6.237.491 | 3.009.152 | 174.477.839 |
| Marketing, Sales and Distribution Expenses (-) | (9.903.261) | - | (512.616) | - | (10.415.877) |
| General Administration Expenses (-) | (62.306.122) | (3.111.052) | (4.695.460) | 41.015 | (70.071.619) |
| Research and Development Expenses (-) | (9.376.632) | - | - | 23.713 | (9.352.919) |
| Other Operating Income | 17.982.353 | 691.818 | 809.773 | (110.698) | 19.373.246 |
| Other Operating Expenses(-) | <u>(39.624.793)</u> | <u>(1.160.931)</u> | <u>(215)</u> | <u>4.406.184</u> | <u>(36.379.755)</u> |
| OPERATING PROFIT / (LOSS) | 55.470.562 | 2.952.014 | 1.838.973 | 7.369.366 | 67.630.915 |
| Financial Income | 107.847.780 | 178.705 | 29.196.486 | (9.996.156) | 127.226.815 |
| Financial Expenses (-) | <u>(101.614.973)</u> | <u>(1.213)</u> | <u>(29.015.355)</u> | <u>47.946</u> | <u>(130.583.595)</u> |
| PROFIT/(LOSS) FROM CONTINUING ACTIVITIES BEFORE TAX | 61.703.369 | 3.129.506 | 2.020.104 | (2.578.844) | 64.274.135 |
| Tax Income/(Expense) for the Period | (9.645.120) | (1.243.344) | (394.423) | - | (11.282.887) |
| Deferred Tax Income / (Expense) | <u>(489.161)</u> | <u>527.184</u> | <u>(13.601)</u> | <u>33.918</u> | <u>58.340</u> |
| Tax Income/(Expense) Related to Continuing Activities | <u>(10.134.281)</u> | <u>(716.160)</u> | <u>(408.024)</u> | <u>33.918</u> | <u>(11.224.547)</u> |
| PROFIT/(LOSS) FOR THE PERIOD ON CONTINUING ACTIVITIES | 51.569.088 | 2.413.346 | 1.612.080 | (2.544.926) | 53.049.588 |
| PROFIT/(LOSS) FOR THE PERIOD | 51.569.088 | 2.413.346 | 1.612.080 | (2.544.926) | 53.049.588 |
| OTHER COMPREHENSIVE PROFIT/(LOSS) | - | - | - | - | - |
| TOTAL COMPREHENSIVE PROFIT/(LOSS) | <u>51.569.088</u> | <u>2.413.346</u> | <u>1.612.080</u> | <u>(2.544.926)</u> | <u>53.049.588</u> |

* Chemistry sector includes the financial data related to the Parent Company.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

3. Segment Reporting (continued)

As of 31 December 2008, segment reporting consists of the following (TL):

| | Chemistry * | Textile | Marketing | Classification and Elimination | Total |
|----------------------------|-----------------------------|--------------------------|---------------------------|--------------------------------------|-----------------------------|
| ASSETS | | | | | |
| Current Assets | 579.816.424 | 10.535.100 | 116.961.977 | (98.237.358) | 609.076.143 |
| Cash and Cash Equivalents | 60.259.117 | 582.063 | 2.742.375 | - | 63.583.555 |
| Trade Receivables | | | | | |
| - Other Trade Receivables | 283.008.870 | 133.918 | 75.727.971 | - | 358.870.759 |
| - Due from Related Parties | 96.761.228 | 6.689.305 | 19.662.227 | (97.885.066) | 25.227.694 |
| Other Receivables | 27.673.552 | 13.035 | 17.661.628 | - | 45.348.215 |
| Inventories | 96.390.405 | 2.280.372 | 460.460 | (352.292) | 98.778.945 |
| Other Current Assets | 15.723.252 | 836.407 | 707.316 | - | 17.266.975 |
| Non-current Assets | 514.437.396 | 16.347.311 | 2.665.198 | (14.042.273) | 519.407.632 |
| Trade Receivables | 12.665.408 | - | - | - | 12.665.408 |
| Other Receivables | 9.417 | - | - | - | 9.417 |
| Financial Assets | 27.138.270 | 39.361 | 39.388 | (19.217.238) | 7.999.781 |
| Tangible Assets | 439.250.455 | 13.486.286 | 2.616.161 | (813.686) | 454.539.216 |
| Intangible Assets | 194.305 | 2.821.664 | 9.649 | - | 3.025.618 |
| Goodwill | - | - | - | 5.988.651 | 5.988.651 |
| Other Non-current Assets | <u>35.179.541</u> | <u>-</u> | <u>-</u> | <u>-</u> | <u>35.179.541</u> |
| TOTAL ASSETS | <u>1.094.253.820</u> | <u>26.882.411</u> | <u>119.627.175</u> | <u>(112.279.631)</u> | <u>1.128.483.775</u> |

* Chemistry sector includes the financial data related to the Parent Company.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

3. Segment Reporting (continued)

As of 31 December 2008, segment reporting consists of the following (TL) (continued):

| | Chemistry * | Textile | Marketing | Classification and Elimination | Total |
|---|----------------------|-------------------|--------------------|--------------------------------------|----------------------|
| LIABILITIES | | | | | |
| Short Term Liabilities | 250.058.121 | 2.378.809 | 112.242.501 | (98.028.250) | 266.651.181 |
| Financial Debts | 100.899.481 | - | 17.582.933 | - | 118.482.414 |
| Trade Payables | | | | | |
| - Other Trade Payables | 91.710.694 | 1.031.094 | 1.428.449 | - | 94.170.237 |
| - Due to Related Parties | 21.755.540 | 849.258 | 92.370.318 | (98.028.250) | 16.946.866 |
| Other Payables | 2.510.353 | 182.199 | 600.818 | - | 3.293.370 |
| Taxes Payable on Profit for the Current Period | 7.915.984 | - | 187.162 | - | 8.103.146 |
| Debt Provisions | 3.554.622 | 172.724 | 72.821 | - | 3.800.167 |
| Other Short Term Liabilities | 21.711.447 | 143.534 | - | - | 21.854.981 |
| Long Term Liabilities | 145.848.909 | 2.431.760 | 383.594 | (41.822) | 148.622.441 |
| Financial Debts | 121.089.861 | - | - | - | 121.089.861 |
| Provisions for | | | | | |
| Employee Benefits | 7.445.359 | 1.411.592 | 497.431 | - | 9.354.382 |
| Deferred Tax Liability | 17.313.689 | 1.020.168 | (113.837) | (41.822) | 18.178.198 |
| EQUITY | 698.346.790 | 22.071.842 | 7.001.080 | (14.209.559) | 713.210.153 |
| Parent Company Equity | 698.346.790 | 22.071.842 | 7.001.080 | (29.067.886) | 698.351.826 |
| Paid-in Capital | 365.174.673 | 8.465.590 | 17.440.373 | (281.080.636) | 110.000.000 |
| Inflation Adjustment on Share Capital | - | - | - | 255.174.673 | 255.174.673 |
| Issue Premiums | 1.669.549 | - | - | (1.625.943) | 43.606 |
| Restricted Profit Reserves | 119.337.456 | 10.254.838 | 2.585.771 | (89.401.474) | 42.776.591 |
| Retained Earnings / (Accumulated Losses) | 138.163.566 | 811.682 | (14.519.700) | 92.994.199 | 217.449.747 |
| Net Profit / (Loss) for the Period | 74.001.546 | 2.539.732 | 1.494.636 | (5.128.705) | 72.907.209 |
| Non-controlling Interests | - | - | - | <u>14.858.327</u> | <u>14.858.327</u> |
| TOTAL LIABILITIES AND EQUITY | <u>1.094.253.820</u> | <u>26.882.411</u> | <u>119.627.175</u> | <u>(112.279.631)</u> | <u>1.128.483.775</u> |

* Chemistry sector includes the financial data related to the Parent Company.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

3. Segment Reporting (continued)

As of 31 December 2008, segment reporting consists of the following (TL) (continued):

| | Chemistry * | Textile | Marketing | Classification and Elimination | Total |
|---|----------------------|---------------------|----------------------|--------------------------------------|----------------------|
| CONTINUING ACTIVITIES | | | | | |
| Sales Income (net) | 885.439.640 | 29.652.066 | 343.403.588 | (350.030.567) | 908.464.727 |
| Cost of Sales (-) | <u>(791.723.286)</u> | <u>(25.562.820)</u> | <u>(366.450.083)</u> | <u>356.576.848</u> | <u>(827.159.341)</u> |
| GROSS PROFIT / (LOSS) | 93.716.354 | 4.089.246 | (23.046.495) | 6.546.281 | 81.305.386 |
| Marketing, Sales and Distribution Expenses (-) | (6.073.093) | - | - | 4.218.744 | (1.854.349) |
| General Administration Expenses (-) | (30.875.251) | (2.356.442) | (5.488.297) | (553.586) | (39.273.576) |
| Research and Development Expenses (-) | (9.216.640) | - | - | 36.230 | (9.180.410) |
| Other Operating Income | 13.080.815 | 697.535 | 702.425 | (104.504) | 14.376.271 |
| Other Operating Expenses(-) | <u>(9.819.724)</u> | <u>(83.254)</u> | <u>(394.706)</u> | <u>6.187.285</u> | <u>(4.110.399)</u> |
| OPERATING PROFIT/(LOSS) | 50.812.461 | 2.347.085 | (28.227.073) | 16.330.450 | 41.262.923 |
| Financial Income | 162.895.293 | 604.740 | 30.487.066 | (41.660.726) | 152.326.373 |
| Financial Expenses (-) | <u>(123.640.777)</u> | <u>(81.527)</u> | <u>(418.953)</u> | <u>22.434.327</u> | <u>(101.706.930)</u> |
| PROFIT/(LOSS) FROM CONTINUING ACTIVITIES BEFORE TAX | 90.066.977 | 2.870.298 | 1.841.040 | (2.895.949) | 91.882.366 |
| Tax Income/(Expense) for the Period | (14.795.878) | (583.960) | (370.271) | - | (15.750.109) |
| Deferred Tax Income / (Expense) | <u>(1.269.553)</u> | <u>253.394</u> | <u>23.867</u> | <u>76.445</u> | <u>(915.847)</u> |
| Tax Income/(Expense) Related to Operating Activities | <u>(16.065.431)</u> | <u>(330.566)</u> | <u>(346.404)</u> | <u>76.445</u> | <u>(16.665.956)</u> |
| PROFIT/(LOSS) FOR THE PERIOD ON CONTINUING ACTIVITIES | <u>74.001.546</u> | <u>2.539.732</u> | <u>1.494.636</u> | <u>(2.819.504)</u> | <u>75.216.410</u> |
| PROFIT/(LOSS) FOR THE PERIOD | <u>74.001.546</u> | <u>2.539.732</u> | <u>1.494.636</u> | <u>(2.819.504)</u> | <u>75.216.410</u> |
| OTHER COMPREHENSIVE PROFIT/(LOSS) | - | - | - | - | - |
| TOTAL COMPREHENSIVE PROFIT/(LOSS) | <u>74.001.546</u> | <u>2.539.732</u> | <u>1.494.636</u> | <u>(2.819.504)</u> | <u>75.216.410</u> |

* Chemistry sector includes the financial data related to the Parent Company.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

3. Segment Reporting (continued)

Distribution of depreciation expenses per segments stated in the statement of comprehensive income for the year ended 31 December 2009 is as follows (TL):

| | <u>Chemistry*</u> | <u>Textile</u> | <u>Marketing</u> | <u>Total</u> |
|---|-------------------|------------------|------------------|-------------------|
| Tangible Assets | 46.678.391 | 2.708.583 | 140.356 | 49.527.330 |
| Intangible Assets | <u>969.005</u> | <u>219.055</u> | <u>5.439</u> | <u>1.193.499</u> |
| Total depreciation and amortisation for the current year | <u>47.647.396</u> | <u>2.927.638</u> | <u>145.795</u> | <u>50.720.829</u> |

Distribution of depreciation expenses per segments stated in the statement of comprehensive income for the year ended 31 December 2008 is as follows (TL):

| | <u>Chemistry*</u> | <u>Textile</u> | <u>Marketing</u> | <u>Total</u> |
|--|-------------------|------------------|------------------|-------------------|
| Tangible Assets | 34.512.904 | 2.592.050 | 158.868 | 37.263.822 |
| Intangible Assets | <u>176.593</u> | <u>216.386</u> | <u>8.084</u> | <u>401.063</u> |
| Total depreciation and amortisation for the current year | <u>34.689.497</u> | <u>2.808.436</u> | <u>166.952</u> | <u>37.664.885</u> |

* Chemistry sector includes the financial data related to the Parent Company.

4. Cash and Cash Equivalents

Cash and cash equivalents consist of the following (TL)

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|------------------------------------|-------------------------|-------------------------|
| Cash | 104.435 | 134.711 |
| Banks (Note 26 (i)) | 101.666.427 | 43.545.402 |
| - TL demand deposit | 7.861.122 | 1.968.990 |
| - Foreign currency demand deposit | 2.666.130 | 4.891.818 |
| - TL time deposit * | 39.459.748 | 11.358.136 |
| - Foreign currency time deposit ** | 51.679.427 | 25.326.458 |
| Cheques received | 9.901.617 | 19.903.442 |
| Other | <u>440.742</u> | <u>-</u> |
| Total | <u>112.113.221</u> | <u>63.583.555</u> |

* As of 31 December 2009 the interest rate on TL time deposit accounts varies between 6,80% and 10,60% (31 December 2008 - 16,55% - 16,65%).

** As of 31 December 2009, the interest rates on USD time deposit accounts vary between 1,65% and 3,35%. There are no Euro deposit accounts (31 December 2008 - USD 3 % - Euro 7 %).

The sum of cash balances and cheques received is stated as "Other" in the Credit Risk Table (Note 26 (i)).

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

5. Financial Assets

Financial assets consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---------------------------------------|-------------------------|-------------------------|
| Subsidiaries; | | |
| Aksa Egypt Acrylic Fiber Industry SAE | 78.695 | 78.695 |
| Fitco BV | 7.863.032 | 7.863.032 |
| Akgirişim Kimya ve Ticaret A.Ş. | 58.000 | 58.000 |
| Other long term financial assets | <u>54</u> | <u>54</u> |
| Total | <u>7.999.781</u> | <u>7.999.781</u> |

6. Financial Liabilities

Financial liabilities consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Short term bank loans | 106.671.792 | 117.676.634 |
| Principal payments of long term bank loans and related interests | <u>35.168.766</u> | <u>805.780</u> |
| Short term financial liabilities | 141.840.558 | 118.482.414 |
| Long term financial liabilities | <u>137.400.143</u> | <u>121.089.861</u> |
| Total financial liabilities (Note 26 (ii)) | <u>279.240.701</u> | <u>239.572.275</u> |

The maturities of long term loans are 15 December 2014 and 30 December 2014.

As of 31 December 2009, the interest rate on short term TL loans is 8%; the interest rate on USD loans varies between 0,85 % and 4,79% (31 December 2008 -TL loans: 14,50% - 17%; USD loans: 2,71% - 10,52%).

As of 31 December 2009, the interest rate on long term USD bank loans vary between 1,99% and 5,63% (31 December 2008 - USD loans: 4,02% - 5,63%).

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

7. Trade Receivables and Payables

Short term trade receivables consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Customers | 171.545.281 | 136.111.961 |
| Notes receivable and post-dated cheques | 151.705.502 | 225.175.376 |
| Rediscount on receivables (-) | (1.641.101) | (2.416.578) |
| Doubtful trade receivables (Note 26(i)) | 26.276.052 | 2.247.869 |
| Provision for doubtful trade receivables (-) (Note 26(i)) | (26.276.052) | (2.247.869) |
| Total other trade receivables * | <u>321.609.682</u> | <u>358.870.759</u> |
| Trade receivables from related parties | 6.674.363 | 25.424.800 |
| Rediscount (-) | (92.958) | (197.106) |
| Trade receivables from related parties (Notes 25 and 26(i)) | <u>6.581.405</u> | <u>25.227.694</u> |
| Total short term trade receivables | <u>328.191.087</u> | <u>384.098.453</u> |

Changes in provisions for doubtful trade receivables as of 31 December 2009 and 2008 are set out in the table below (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|----------------------|-------------------------|-------------------------|
| Opening balance | 2.247.869 | 1.412.641 |
| Provisions (Note 18) | <u>24.028.183</u> | <u>835.228</u> |
| Closing balance | <u>26.276.052</u> | <u>2.247.869</u> |

Long term trade receivables consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Notes receivable and post-dated cheques | 11.934.514 | 14.159.712 |
| Rediscount on receivables (-) | (202.209) | (1.494.304) |
| Total long term trade receivables * | <u>11.732.305</u> | <u>12.665.408</u> |

* The sum of short and long term other trade receivables is stated as "Other Party" in the Credit Risk Table in Note 26(i).

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

7. Trade Receivables and Payables (continued)

Trade payables consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Suppliers | 156.303.432 | 95.601.186 |
| Notes payable | 250.000 | - |
| Rediscount on payables (-) | (<u>295.054</u>) | (<u>1.430.949</u>) |
| Other trade payables | <u>156.258.378</u> | <u>94.170.237</u> |
| Short term trade payables to related parties | 13.145.168 | 16.946.866 |
| Long term trade payables to related parties | 2.836.800 | - |
| Rediscount (-) | (<u>521.392</u>) | - |
| Trade payables to related parties (Note 25) | <u>15.460.576</u> | <u>16.946.866</u> |
| Total trade payables (Note 26 (ii)) | <u>171.718.954</u> | <u>111.117.103</u> |

8. Other Receivables and Payables

Short term other receivables consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| VAT receivable | 31.928.394 | 27.161.696 |
| Other receivables | 263.617 | 253.349 |
| Due from personnel | 388.310 | 193.158 |
| Deposits and guarantees given | <u>203.020</u> | <u>59.255</u> |
| Other receivables * | <u>32.783.341</u> | <u>27.667.458</u> |
| Other receivables from related parties (Note 25 and Note 26 (i)) | <u>10.049.025</u> | <u>17.680.757</u> |
| Total other receivables | <u>42.832.366</u> | <u>45.348.215</u> |

Long term other receivables consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---------------------------------|-------------------------|-------------------------|
| Deposits and guarantees given * | <u>16.478</u> | <u>9.417</u> |

* The sum of short and long term other receivables is stated as "Other Party" in the Credit Risk Table (Note 26 (i)).

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

8. Other Receivables and Payables (continued)

Other payables consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Taxes, duties and other withholdings payable | 2.897.832 | 1.879.354 |
| Social security premiums payable | 1.788.375 | 1.378.191 |
| Due to personnel | 21.593 | 16.203 |
| Other miscellaneous debts | 25.022 | 15.776 |
| Deposits and guarantees received | <u>1.036</u> | <u>1.036</u> |
| Other payables | <u>4.733.858</u> | <u>3.290.560</u> |
| Other payables to related parties (Note 25) | <u>2.912</u> | <u>2.810</u> |
| Total other payables (Note 26 (ii)) | <u>4.736.770</u> | <u>3.293.370</u> |

9. Inventories

Inventories consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|-----------------------------------|-------------------------|-------------------------|
| Raw materials and supplies | 81.816.675 | 64.934.273 |
| Semi-finished goods | 11.152.733 | 9.419.137 |
| Finished goods | 26.115.250 | 26.663.522 |
| Trade goods | 1.764.545 | 460.460 |
| Other inventories | 147.699 | - |
| Inventory provision (-) (Note 18) | <u>(6.926.499)</u> | <u>(2.698.447)</u> |
| | <u>114.070.403</u> | <u>98.778.945</u> |

As of 31 December 2009 and 2008, changes in inventory provision in the respective periods are set out below (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Opening balance | 2.698.447 | - |
| Provisions no longer required (-) (Note 20) | (2.698.447) | - |
| Provisions made (Note 18) | <u>6.926.499</u> | <u>2.698.447</u> |
| Closing balance | <u>6.926.499</u> | <u>2.698.447</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

10. Tangible Assets

Tangible assets consist of the following (TL) :

As of 31 December 2009;

| Cost | Opening 1 January 2009 | Additions | Transfers | Capitalized Finance Cost | Disposals | Closing 31 December 2009 |
|---------------------------------|---------------------------|---------------------|----------------------|--------------------------------|--------------------|-----------------------------|
| Land | 59.187.145 | - | - | - | - | 59.187.145 |
| Land improvements | 34.899.461 | 6.124 | 569.494 | - | - | 35.475.079 |
| Buildings | 100.328.805 | 24.975 | 10.330.857 | - | (1.089.532) | 109.595.105 |
| Machinery and equipment | 625.757.439 | 13.053.906 | 105.404.218 | - | (16.053) | 744.199.510 |
| Motor vehicles | 881.609 | 429.379 | - | - | (54.394) | 1.256.594 |
| Furniture and fixtures | 14.055.668 | 783.213 | 52.139 | - | (160.318) | 14.730.702 |
| Other tangible assets | 9.219 | - | - | - | - | 9.219 |
| Investments in progress | <u>57.024.162</u> | <u>142.362.531</u> | <u>(117.135.321)</u> | <u>1.683.972</u> | <u>-</u> | <u>83.935.344</u> |
| Sub total | <u>892.143.508</u> | <u>156.660.128</u> | <u>(778.613)</u> | <u>1.683.972</u> | <u>(1.320.297)</u> | <u>1.048.388.698</u> |
| Accumulated depreciation (-) | | | | | | |
| Land improvements | (24.426.683) | (1.492.989) | - | - | - | (25.919.672) |
| Buildings | (29.171.481) | (2.142.410) | - | - | 138.736 | (31.175.155) |
| Machinery and equipment | (371.636.476) | (47.691.466) | - | - | 16.054 | (419.311.888) |
| Motor vehicles | (803.309) | (56.064) | - | - | 56.654 | (802.719) |
| Furniture and fixtures | (11.557.211) | (632.093) | - | - | 149.686 | (12.039.618) |
| Other tangible assets | (9.132) | (87) | - | - | - | (9.219) |
| Sub total | <u>(437.604.292)</u> | <u>(52.015.109)</u> | <u>-</u> | <u>-</u> | <u>361.130</u> | <u>(489.258.271)</u> |
| Net Book Value | <u>454.539.216</u> | <u>104.645.019</u> | <u>(778.613)</u> | <u>1.683.972</u> | <u>(959.167)</u> | <u>559.130.427</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

10. Tangible Assets (continued)

Tangible assets consist of the following (TL) (continued) :

As of 31 December 2008;

| Cost | Opening 1 January 2008 | Additions | Transfers | Capitalized Finance Cost | Disposals | Closing 31 December 2008 |
|---------------------------------|---------------------------|---------------------|----------------------|--------------------------------|--------------------|-----------------------------|
| Land | 54.577.547 | - | 4.609.598 | - | - | 59.187.145 |
| Land improvements | 31.667.828 | - | 3.231.633 | - | - | 34.899.461 |
| Buildings | 79.206.377 | 43.236 | 21.490.209 | - | (411.017) | 100.328.805 |
| Machinery and equipment | 495.005.286 | 21.648.792 | 109.635.493 | - | (532.132) | 625.757.439 |
| Motor vehicles | 1.207.263 | 2.354 | - | - | (328.008) | 881.609 |
| Furniture and fixtures | 14.357.832 | 468.449 | 592.373 | - | (1.362.986) | 14.055.668 |
| Other tangible assets | 9.899 | - | - | - | (680) | 9.219 |
| Investments in progress | <u>89.719.957</u> | <u>83.225.797</u> | <u>(139.759.909)</u> | <u>24.667.878</u> | <u>(829.561)</u> | <u>57.024.162</u> |
| Sub total | <u>765.751.989</u> | <u>105.388.628</u> | <u>(200.603)</u> | <u>24.667.878</u> | <u>(3.464.384)</u> | <u>892.143.508</u> |
| Accumulated depreciation (-) | | | | | | |
| Land improvements | (23.052.115) | (1.374.568) | - | - | - | (24.426.683) |
| Buildings | (27.544.920) | (1.703.197) | - | - | 76.636 | (29.171.481) |
| Machinery and equipment | (337.497.494) | (34.664.712) | - | - | 525.730 | (371.636.476) |
| Motor vehicles | (1.067.350) | (49.895) | - | - | 313.936 | (803.309) |
| Furniture and fixtures | (12.008.773) | (901.290) | - | - | 1.352.852 | (11.557.211) |
| Other tangible assets | (9.297) | (515) | - | - | 680 | (9.132) |
| Sub total | <u>(401.179.949)</u> | <u>(38.694.177)</u> | <u>-</u> | <u>-</u> | <u>2.269.834</u> | <u>(437.604.292)</u> |
| Net Book Value | <u>364.572.040</u> | <u>66.694.451</u> | <u>(200.603)</u> | <u>24.667.878</u> | <u>(1.194.550)</u> | <u>454.539.216</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

11. Intangible Assets

Intangible assets consist of the following (TL) :

As of 31 December 2009;

| Cost ; | Opening 1 January 2009 | Additions | Transfers and Disposals | Closing 31 December 2009 |
|---|---------------------------|--------------------|----------------------------|-----------------------------|
| Rights | 1.469.043 | - | 178.870 | 1.647.913 |
| Intangible assets at development phase | - | 6.554.699 | 562.133 | 7.116.832 |
| Special costs | 5.921.626 | 42.888 | 37.612 | 6.002.126 |
| Other intangible assets | <u>1.376.044</u> | <u>170.990</u> | <u>(69.292)</u> | <u>1.477.742</u> |
| Sub total | <u>8.766.713</u> | <u>6.768.577</u> | <u>709.323</u> | <u>16.244.613</u> |
| Accumulated amortisation (-) | | | | |
| Rights | (1.448.486) | (15.335) | - | (1.463.821) |
| Intangible assets at development phase | - | (830.297) | - | (830.297) |
| Special costs | (3.094.869) | (218.570) | 62.510 | (3.250.929) |
| Other intangible assets | <u>(1.197.740)</u> | <u>(129.300)</u> | <u>-</u> | <u>(1.327.040)</u> |
| Sub total | <u>(5.741.095)</u> | <u>(1.193.502)</u> | <u>62.510</u> | <u>(6.872.087)</u> |
| Net Book Value | <u>3.025.618</u> | <u>5.575.075</u> | <u>771.833</u> | <u>9.372.526</u> |

As of 31 December 2008;

| Cost ; | Opening 1 January 2008 | Additions | Transfers and Disposals | Closing 31 December 2008 |
|------------------------------|---------------------------|------------------|----------------------------|-----------------------------|
| Rights | 1.615.798 | 8.976 | (155.731) | 1.469.043 |
| Special costs | 5.705.488 | 15.535 | 200.603 | 5.921.626 |
| Other intangible assets | <u>1.338.568</u> | <u>37.476</u> | <u>-</u> | <u>1.376.044</u> |
| Sub total | <u>8.659.854</u> | <u>61.987</u> | <u>44.872</u> | <u>8.766.713</u> |
| Accumulated amortisation (-) | | | | |
| Rights | (1.580.385) | (23.437) | 155.336 | (1.448.486) |
| Special costs | (2.878.436) | (216.433) | - | (3.094.869) |
| Other intangible assets | <u>(1.036.547)</u> | <u>(161.193)</u> | <u>-</u> | <u>(1.197.740)</u> |
| Sub total | <u>(5.495.368)</u> | <u>(401.063)</u> | <u>155.336</u> | <u>(5.741.095)</u> |
| Net Book Value | <u>3.164.486</u> | <u>(339.076)</u> | <u>200.208</u> | <u>3.025.618</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

12. Goodwill

Goodwill consists of the following (TL) :

As of 31 December 2009;

| | <u>Opening 1 January 2009</u> | <u>Additions</u> | <u>Disposals</u> | <u>Closing 31 December 2009</u> |
|--------------------------------|-----------------------------------|------------------|------------------|-------------------------------------|
| Ak-Tops Tekstil Sanayi A.Ş. | 5.988.651 | - | - | 5.988.651 |
| | <u>5.988.651</u> | <u>-</u> | <u>-</u> | <u>5.988.651</u> |

As of 31 December 2008;

| | <u>Opening 1 January 2008</u> | <u>Additions</u> | <u>Disposals</u> | <u>Closing 31 December 2008</u> |
|--------------------------------|-----------------------------------|------------------|------------------|-------------------------------------|
| Ak-Tops Tekstil Sanayi A.Ş. | 5.988.651 | - | - | 5.988.651 |
| | <u>5.988.651</u> | <u>-</u> | <u>-</u> | <u>5.988.651</u> |

13. Provisions, Contingent Assets and Liabilities

Debt provisions consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Provision for litigation | 741.796 | 734.420 |
| Provision for unused leaves | 905.860 | 933.201 |
| Provision for contingent loss related to derivative instruments (Note 27) | - | 2.059.724 |
| Provisions for other debts and expenses | <u>465.839</u> | <u>72.822</u> |
| | <u>2.113.495</u> | <u>3.800.167</u> |

Taxes payable on profit for the current period consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Current period tax provision (Note 23) | 11.282.887 | 15.750.109 |
| Prepaid taxes and funds (-) | <u>(10.061.384)</u> | <u>(7.646.963)</u> |
| | <u>1.221.503</u> | <u>8.103.146</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

13. Provisions, Contingent Assets and Liabilities (continued)

Contingent assets and liabilities consist of the following (TL) :

- a) Guarantees, sureties, and mortgages given to third parties in the name of the Company's own corporate body consist of the following(TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|------------------|-------------------------|-------------------------|
| Guarantees given | <u>255.394.539</u> | <u>202.569.801</u> |

As of 31 December 2009, the ratio of the sum of all guarantees, sureties, and mortgages given by the Company to the total equity of the Company is 33% (31 December 2008 - 28%).

- b) Guarantee letters received for short term trade receivables, guarantee cheques and notes, mortgages, and other guarantees received consist of the following (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--------------------------------------|-------------------------|-------------------------|
| Guarantee letters received | 12.424.615 | 10.542.915 |
| Guarantee cheques and notes received | 60.645.709 | 31.218.747 |
| Mortgages received | 11.000.000 | 37.115.995 |
| Other guarantees received * | <u>103.410.274</u> | <u>113.369.054</u> |
| | <u>187.480.598</u> | <u>192.246.711</u> |

* Other guarantees comprise confirmed/unconfirmed letter of credit, direct debiting system limits, Eximbank limits, and other credit letters.

- c) Guarantee notes, guarantee letters, and mortgages received from supplier firms consist of the following (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|----------------------------|-------------------------|-------------------------|
| Guarantee letters received | 1.281.032 | 271.915 |
| Guarantee notes received | 631.110 | 2.240.136 |
| Guarantee cheques received | <u>4.601.606</u> | <u>128.874</u> |
| | <u>6.513.748</u> | <u>2.640.925</u> |

- d) As of 31 December 2009 the ongoing litigation commenced by the Parent Company and its Subsidiaries against third parties amount to TL 20.180.606 and USD 7.492.584 (31 December 2008 - TL 1.276.824 and USD 357.584).

- e) As of 31 December 2009, the ongoing litigation commenced by third parties against the Parent Company and its Subsidiaries amounts to TL 307.198 (31 December 2008 - TL 309.598).

Changes in provisions for litigation as of 31 December 2009 and 2008 consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Opening balance | 734.420 | 2.844.992 |
| Provisions no longer required (-) (Note 20) | (77.942) | (2.394.167) |
| Provisions made (Note 18) | <u>85.318</u> | <u>283.595</u> |
| Closing balance | <u>741.796</u> | <u>734.420</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

14. Employee Benefits

Liabilities related to employee benefits consist of provision for termination indemnity as in the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Opening balance | 9.354.382 | 9.592.710 |
| Provisions made (Note 18) | 607.510 | 306.679 |
| Provisions for seniority incentive premium (Note 18) | 1.929.008 | - |
| Provisions no longer required (-) (Note 20) | (370.873) | (545.007) |
| Closing balance | <u>11.520.027</u> | <u>9.354.382</u> |

15. Other Assets and Liabilities

Other current assets consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--------------------------------------|-------------------------|-------------------------|
| Order advances given for inventories | 3.948.451 | 1.163.612 |
| Other VAT | 15.771.011 | 10.833.914 |
| Deferred VAT | 14.124.754 | 3.591.061 |
| Prepaid taxes and funds | 15.715 | 95.382 |
| Advances given to personnel | 1.293.601 | 1.248.922 |
| Expenses related to future months | 882.631 | 297.831 |
| Job advances | <u>96.961</u> | <u>36.253</u> |
| | <u>36.133.124</u> | <u>17.266.975</u> |

Other long term assets consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Expenses related to future years | 14.544 | - |
| Order advances given for tangible assets | <u>51.352.894</u> | <u>35.179.541</u> |
| | <u>51.367.438</u> | <u>35.179.541</u> |

Other short term liabilities consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---------------------------------|-------------------------|-------------------------|
| Other VAT | 15.771.011 | 10.833.914 |
| Expense accruals | 923.727 | 153.544 |
| Income related to future months | - | 630.000 |
| Order advances received | <u>9.951.682</u> | <u>10.237.523</u> |
| | <u>26.646.420</u> | <u>21.854.981</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

16. Equity

(a) Share Capital:

The shareholding structure of the Parent Company is as follows (TL):

| <u>Name</u> | <u>31 December 2009</u> | | <u>31 December 2008</u> | |
|---|-------------------------|----------------------|-------------------------|----------------------|
| | <u>Shareholding</u> | <u>Nominal Value</u> | <u>Shareholding</u> | <u>Nominal Value</u> |
| Akkök Sanayi Yatırım ve Geliştirme A.Ş. | 39,58% | 73.223.000 | 39,58% | 43.546.625 |
| Emniyet Tic. ve San. A.Ş. | 18,72% | 34.632.000 | 18,72% | 20.596.070 |
| Other * | 41,70% | <u>77.145.000</u> | 41,70% | <u>45.857.305</u> |
| | | <u>185.000.000</u> | | <u>110.000.000</u> |
| Capital adjustment differences | | <u>195.174.673</u> | | <u>255.174.673</u> |
| Total adjusted capital | | <u>380.174.673</u> | | <u>365.174.673</u> |

* Represents shareholding of less than 10%.

The Parent Company's registered capital limit is TL 425.000.000 and its issued capital has been increased from TL 110.000.000 to TL 185.000.000. Of the increased portion of TL 75.000.000, a total of TL 60.000.000 is provided from inflation adjustment differences and the balance of TL 15.000.000 is provided through addition of the first dividends allocated from 2008 profit to the share capital. Bonus shares are deposited to the shareholders' accounts as of 30 June 2009, and the capital increase is registered at 1 July 2009.

(b) Restricted Profit Reserves:

Restricted profit reserves consist of the legal reserves and profit on sales of investments as follows (TL);

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|-------------------------------|-------------------------|-------------------------|
| Legal reserves | 19.549.570 | 16.579.576 |
| Profit on sale of investments | <u>26.316.640</u> | <u>26.197.015</u> |
| | <u>45.866.210</u> | <u>42.776.591</u> |

Legal reserves, which are divided as First Legal Reserve and Second Legal Reserve as per the Turkish Commercial Code, are appropriated as below:

- a) First Legal Reserve: Appropriated out of net profit at the rate of 5% until such reserve is equal to 20% of issued and fully paid capital.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

16. Equity (continued)

(b) Restricted Profit Reserves (continued):

- b) Second Legal Reserve: Appropriated out of net profit at the rate of 10% of distributions after providing for First Legal Reserve and an amount equal to 5% of capital as dividends.

Legal reserves which do not exceed one half of share capital may only be used to absorb losses or for purposes of continuity of the business in times of business difficulties and to prevent unemployment or lessen its effects.

(c) Retained Earnings / (Accumulated Losses) :

Retained earnings/(accumulated losses) in the respective periods is as follows (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|-------------------------------|-------------------------|-------------------------|
| Retained earnings | 217.449.747 | 238.916.635 |
| 2007 profit transfer | - | 4.730.127 |
| 2008 profit transfer | 72.907.209 | - |
| Capital increase | (15.000.000) | - |
| Transfer to reserves | (2.969.994) | - |
| Profit on sale of investments | <u>(119.625)</u> | <u>(26.197.015)</u> |
| | <u>272.267.337</u> | <u>217.449.747</u> |

Distribution of retained earnings/(accumulated losses) is as follows (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Retained earnings/(Accumulated losses) | 75.690.769 | 21.170.548 |
| Extraordinary reserves | 56.768.988 | 56.768.988 |
| Differences arising from inflation adjustment in equity | 138.677.573 | 138.677.573 |
| Legal reserves of subsidiaries | 1.076.375 | 779.006 |
| Extraordinary reserves of subsidiaries | <u>53.632</u> | <u>53.632</u> |
| | <u>272.267.337</u> | <u>217.449.747</u> |

As per the Communiqué Nr. XI/29, "Paid-in Capital, Issue Premiums and Restricted Reserves" are recognized over the totals stated in the legal books, and the differences arising upon valuations made in accordance with TAS/TFRS are correlated with the retained earnings/accumulated losses. As per the same Communiqué, retained earnings/accumulated losses other than the net profit for the period, are stated in the "Retained Earnings/Accumulated Losses" account together with the extraordinary reserves regarded in essence as retained earnings/accumulated losses.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

16. Equity (continued)

(c) Retained Earnings / (Accumulated Losses) (continued):

Inflation adjustment differences in equity arising upon restatement of share premium, legal and extraordinary reserves are stated below as per the respective periods (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Inflation adjustment in extraordinary reserves | 5.323.651 | 5.323.651 |
| Inflation adjustment in legal reserves | 110.092.166 | 110.092.166 |
| Inflation adjustment in share premium | <u>23.261.756</u> | <u>23.261.756</u> |
| | <u>138.677.573</u> | <u>138.677.573</u> |

Inflation adjustment differences may be used in bonus issue and offsetting losses. Furthermore, inflation adjustment differences arising from reserves bearing no record that disables profit distribution may be used in profit distribution. As of 31 December 2009, the other distributable sources amount to TL 492.672.249.

(d) Non-controlling Interests

Non-controlling interests consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Share capital | 18.468.486 | 18.468.486 |
| Legal reserves | 6.636.771 | 6.339.405 |
| Extraordinary reserves | 192.101 | 192.101 |
| Retained earnings/(accumulated losses) | (13.068.692) | (12.450.866) |
| Profit/(loss) for the period | <u>2.360.271</u> | <u>2.309.201</u> |
| | <u>14.588.937</u> | <u>14.858.327</u> |

17. Sales and Cost of Sales

Sales income consists of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|----------------------|-------------------------|-------------------------|
| Domestic sales | 565.331.700 | 571.602.930 |
| Exports | 405.850.438 | 368.809.872 |
| Other sales | 2.170.383 | 6.871 |
| Sales returns (-) | (4.505.855) | (2.516.832) |
| Sales discounts (-) | (6.932) | (59) |
| Other deductions (-) | <u>(18.668.638)</u> | <u>(29.438.055)</u> |
| | <u>950.171.096</u> | <u>908.464.727</u> |

The electricity sales and steam sales included in the exports for the year ended 31 December 2009 amounts to TL 28.866.872, and TL 9.180.764, respectively (31 December 2008 - None).

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

17. Sales and Cost of Sales (continued)

Cost of sales consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|-----------------------------|-------------------------|-------------------------|
| Cost of finished goods sold | 715.230.856 | 758.513.161 |
| Cost of trade goods sold | 39.732.366 | 39.587.417 |
| Cost of services sold | 18.593.505 | 25.290.510 |
| Cost of other sales | <u>2.136.530</u> | <u>3.768.253</u> |
| | <u>775.693.257</u> | <u>827.159.341</u> |

The sales cost of electricity and steam included in the cost of finished goods sold during the year ended 31 December 2009 amounts to TL 7.145.776, and TL 9.011.571, respectively (31 December 2008 - None).

Cost of goods sold consists of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--------------------------------|-------------------------|-------------------------|
| Raw materials and supplies | 547.291.211 | 601.932.978 |
| Depreciation expense (Note 19) | 26.265.827 | 31.341.386 |
| Overhead | 116.339.786 | 101.797.449 |
| Labor expense | <u>25.334.032</u> | <u>23.441.348</u> |
| | <u>715.230.856</u> | <u>758.513.161</u> |

18. Research and Development Expenses; Marketing, Sales and Distribution Expenses; General Administration Expenses

Research and development expenses, marketing, sales and distribution expenses and general administration expenses consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Research and development expenses | 9.352.919 | 9.180.410 |
| Marketing, sales and distribution expenses | 10.415.877 | 1.854.349 |
| General administration expenses | <u>70.071.619</u> | <u>39.273.576</u> |
| | <u>89.840.415</u> | <u>50.308.335</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

18. Research and Development Expenses; Marketing, Sales and Distribution Expenses; General Administration Expenses (continued)

Research and development expenses, marketing, sales and distribution expenses and general administration expenses consist of the following (TL) (continued):

Marketing, Sales and Distribution Expenses:

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Personnel expenses (Note 19) | 2.446.183 | 1.215.926 |
| Sampling expenses | 149.623 | 76.755 |
| Transportation and rent expenses | 16.148 | 114.366 |
| Travel expenses | 383.516 | 122.767 |
| Fair and exposition expenses | 115.269 | 93.383 |
| Rent expenses | 172.203 | 79.049 |
| Depreciation (Note 19) | 45.121 | 21.674 |
| Communication expenses | 24.414 | 13.138 |
| Advertisement, press and promotion expenses | 16.113 | 1.819 |
| Exports expenses | 6.614.616 | - |
| Other expenses | <u>432.671</u> | <u>115.472</u> |
| | <u>10.415.877</u> | <u>1.854.349</u> |

Research and Development Expenses;

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Personnel expenses (Note 19) | 1.740.520 | 4.144.223 |
| Depreciation (Note 19) | 3.158.516 | 2.669.273 |
| Subcontractor expenses | 146.505 | 389.827 |
| Maintenance, repair, and cleaning expenses | 115.650 | 231.352 |
| Auxiliary material expenses | 3.605.118 | 267.120 |
| Other outsourced benefits and services | 126.937 | 106.722 |
| Other expenses | <u>459.673</u> | <u>1.371.893</u> |
| | <u>9.352.919</u> | <u>9.180.410</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

18. Research and Development Expenses; Marketing, Sales and Distribution Expenses; General Administration Expenses (continued)

Research and development expenses, marketing, sales and distribution expenses and general administration expenses consist of the following (TL) (continued):

General Administration Expenses:

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Personnel expenses (Note 19) | 14.240.291 | 14.652.518 |
| Communication expenses | 396.215 | 578.215 |
| Consultancy expenses | 5.287.479 | 4.912.086 |
| Social expenses | 1.673.132 | 2.799.331 |
| Depreciation (Note 19) | 760.126 | 813.157 |
| Office expenses | 673.129 | 449.242 |
| Insurance expenses | 338.075 | 438.986 |
| Rent expenses | 807.364 | 677.928 |
| Miscellaneous tax expenses | 692.247 | 361.797 |
| Travel expenses | 891.932 | 870.639 |
| Advertisement expenses | 38.424 | 42.926 |
| Disallowable expenses | 1.583.838 | 2.703.056 |
| Provision expenses for doubtful receivables (Note 7) | 24.028.183 | 835.228 |
| Inventory provision expenses (Note 9) | 6.926.499 | 2.698.447 |
| Data processing service expenses | 3.248.471 | 1.948.165 |
| Contribution to common costs | 267.823 | 627.029 |
| Provisions for termination indemnity (Notes 14 and 19) | 607.510 | 306.679 |
| Provisions for leaves (Note 19) | 29.997 | 241.043 |
| Environmental expenses | 624.230 | - |
| Subcontractor expenses | 735.351 | 142.694 |
| Maintenance, repair, and cleaning expenses | 1.062.712 | 909.752 |
| Other outsourced benefits and services | 892.200 | 1.087.143 |
| Court and notary expenses | 169.291 | 51.369 |
| Provision expense related to dividends to the Board of Directors | 465.839 | - |
| Provision expenses related to seniority incentive premium (Notes 14 and 19) | 1.929.008 | - |
| Provision expenses related to litigation (Note 13) | 85.318 | 283.595 |
| Other expenses | <u>1.616.936</u> | <u>842.551</u> |
| | <u>70.071.619</u> | <u>39.273.576</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

19. Expenses by Nature

Depreciation and amortization expenses consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Cost of finished goods sold (Note 17) | 26.265.827 | 31.341.386 |
| Cost of services sold | 2.919.942 | 2.797.725 |
| Cost of other sales | 10.027 | 21.670 |
| Research and development expenses(Note 18) | 3.158.516 | 2.669.273 |
| Marketing expenses (Note 18) | 45.121 | 21.674 |
| General administration expenses (Note 18) | 760.126 | 813.157 |
| Idle section expenses | 16.142.451 | - |
| Intangible assets at development phase | 1.043.893 | - |
| Investments in progress | 30.081 | - |
| Other expenses | 1.418.819 | - |
| Depreciation on inventory | <u>1.413.808</u> | <u>1.430.355</u> |
| | <u>53.208.611</u> | <u>39.095.240</u> |
| Depreciation (Note 10) | 52.015.109 | 38.694.177 |
| Amortisation (Note 11) | <u>1.193.502</u> | <u>401.063</u> |
| | <u>53.208.611</u> | <u>39.095.240</u> |

Employee benefits consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Overhead | 31.544.990 | 29.468.187 |
| Research and development expenses (Note 18) | 1.740.520 | 4.144.223 |
| Marketing and sales expenses (Note 18) | 2.446.183 | 1.215.926 |
| Idle section expenses | 2.680.587 | - |
| General administration expenses (Note 18) | 16.806.807 | 15.200.240 |
| Other expenses | <u>199.857</u> | <u>-</u> |
| | <u>55.418.944</u> | <u>50.028.576</u> |

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Wages and salaries | 41.702.537 | 39.643.944 |
| Catering and transportation expenses | 3.001.794 | 2.683.739 |
| Termination indemnity and payments in lieu of notice | 2.806.819 | 2.281.827 |
| Social benefits | 5.341.278 | 4.871.344 |
| Provision for seniority incentive premium (Note 18) | 1.929.008 | - |
| Provision for termination indemnity and leaves(Note 18) | <u>637.508</u> | <u>547.722</u> |
| | <u>55.418.944</u> | <u>50.028.576</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

20. Other Operating Income and Expenses

Other operating income consists of the following (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Inventory provision | | |
| no longer required (Note 9) | 2.698.447 | - |
| Provision for litigation | | |
| no longer required (Note 13) | 77.942 | 2.394.167 |
| Provision for termination indemnity | | |
| no longer required (Note 14) | 370.873 | 545.007 |
| Provision for leaves no longer required | 57.339 | - |
| Profit on sale of investments* | - | 335.718 |
| Profit on sale of fixed assets | 39.763 | 328.902 |
| Research and development | | |
| incentive premium income** | 11.209.073 | 4.803.565 |
| Other income and profits | <u>4.919.809</u> | <u>5.968.912</u> |
| | <u>19.373.246</u> | <u>14.376.271</u> |

* Ak-Han Bak. Yön. Serv. Hizm. Güven. Malz. A.Ş. was sold on 16 July 2008 to Akkök Sanayi Yatırım ve Geliştirme A.Ş. at a total of TL 399.300 and the resulting profit on sale amounts to TL 335.718.

** The Research and Development (R&D) incentive premium stated in the equity account group in the legal records for the purpose of benefiting from tax advantages will take place within the equity account group in the future reporting periods.

Other operating expenses consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|----------------------------------|-------------------------|-------------------------|
| Commission expenses | 7.773.109 | 2.797.828 |
| Idle section expenses | 19.419.957 | - |
| Prior period expenses and losses | 269.964 | 11.961 |
| Loss on sale of fixed assets | 141.785 | 102.698 |
| Provision expenses | 797.347 | - |
| Start up expenses | 3.262.048 | - |
| Other expenses and losses | <u>4.715.545*</u> | <u>1.197.912</u> |
| | <u>36.379.755</u> | <u>4.110.399</u> |

* TL 4.612.501 of the stated total comprises of the expenditures related to the culture center being constructed in Yalova.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

21. Financial Income

Financial income consists of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Foreign exchange gains | 113.062.956 | 138.271.672 |
| Profit on sale of marketable securities | - | 159.680 |
| Rediscount interest income | 4.924.434 | 6.114.677 |
| Maturity difference income | 5.607.627 | 3.800.769 |
| Interest income | <u>3.631.798</u> | <u>3.979.575</u> |
| | <u>127.226.815</u> | <u>152.326.373</u> |

22. Financial Expenses

Financial expenses consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|-------------------------------|-------------------------|-------------------------|
| Foreign exchange losses | 123.719.198 | 91.929.569 |
| Rediscount interest expenses | 3.367.217 | 5.493.832 |
| Short term borrowing expenses | <u>3.497.180</u> | <u>4.283.529</u> |
| | <u>130.583.595</u> | <u>101.706.930</u> |

23. Tax Assets and Liabilities

a) Corporation Tax;

The corporation tax rate for 2009 is 20% in Turkey (31 December 2008 - 20%). This rate is applicable to the tax base derived upon exemptions and deductions stated in the tax legislation through addition of disallowable expenses to the commercial revenues of the companies.

Tax income and expenses recognized in the statement of comprehensive income are summarized in the following (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---------------------------------|-------------------------|-------------------------|
| Current period Corporation Tax | (11.282.887) | (15.750.109) |
| Deferred tax income / (expense) | <u>58.340</u> | (915.847) |
| Total tax income / (expense) | <u>(11.224.547)</u> | <u>(16.665.956)</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

23. Tax Assets and Liabilities (continued)

a) Corporation Tax (continued);

Calculation of the current period corporation tax stated is made as follows (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|-------------------------|-------------------------|-------------------------|
| Per statutory books | 56.831.917 | 88.522.294 |
| Disallowable expenses | 4.850.891 | 6.905.176 |
| Tax exempt income | (3.075.909) | (13.055.728) |
| Investment earnings | (2.192.465) | (2.271.384) |
| R&D incentive used | - | (1.349.811) |
| Sub total | <u>56.414.434</u> | <u>78.750.547</u> |
| Tax rate (%) | 20 | 20 |
| Tax provision (Note 13) | <u>11.282.887</u> | <u>15.750.109</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

23. Tax Assets and Liabilities (continued)

b) Deferred Tax Assets and Liabilities;

Temporary differences creating a basis for deferred tax calculations and deferred tax assets/liabilities and deferred tax income/expenses are as follows (TL):

| | <u>Temporary Differences</u> | | <u>Deferred Tax Asset/Liability</u> | |
|--|------------------------------|-------------------------|-------------------------------------|-------------------------|
| | <u>31 December 2009</u> | <u>31 December 2008</u> | <u>31 December 2009</u> | <u>31 December 2008</u> |
| Adjustment of rediscount on receivables | 1.964.746 | 2.699.002 | 392.949 | 539.800 |
| Provision for termination indemnity | 9.591.019 | 9.354.382 | 1.918.204 | 1.870.876 |
| Provision for leaves | 905.860 | 933.201 | 181.172 | 186.640 |
| Inventory provision | 5.051.262 | 1.416.879 | 1.010.252 | 283.376 |
| Provision for litigation | 90.931 | 300.521 | 18.186 | 60.104 |
| Provision for contingent losses related to derivative instruments | - | 2.059.724 | - | 411.945 |
| Loan discount adjustment | - | 25.607 | - | 5.121 |
| Expense accrual | 2.083 | 2.088 | 417 | 418 |
| Adjustment on seniority incentive premium | 1.929.008 | - | 385.802 | - |
| Adjustment of electricity cost pending in inventory | 1.715.847 | - | 343.169 | - |
| Transactions related to consolidation | <u>378.701</u> | <u>209.109</u> | <u>75.740</u> | <u>41.822</u> |
| Deferred tax asset | <u>21.629.457</u> | <u>17.000.513</u> | <u>4.325.891</u> | <u>3.400.102</u> |
| Net difference between the book values of tangible/intangible assets and their tax bases | (111.142.225) | (106.460.552) | (22.228.445) | (21.292.110) |
| Loan discount adjustment | (270.069) | - | (54.014) | - |
| Adjustment of rediscount on payables | (816.446) | (1.430.949) | (163.289) | (286.190) |
| Deferred tax liability | <u>(112.228.740)</u> | <u>(107.891.501)</u> | <u>(22.445.748)</u> | <u>(21.578.300)</u> |
| Deferred Tax Asset/(Liability), Net | (90.599.283) | (90.890.988) | (18.119.857) | (18.178.198) |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

23. Tax Assets and Liabilities (continued)

b) Deferred Tax Assets and Liabilities (continued);

Deferred Tax Income / (Expense) (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Current period deferred tax asset/(liability) | (18.119.857) | (18.178.198) |
| Reversal of prior period deferred tax (liability) / asset | <u>18.178.198</u> | <u>17.262.351</u> |
| Deferred tax income / (expense) | <u>58.341</u> | (<u>915.847</u>) |

24. Earnings/(Loss) per Share

Earnings/(loss) per share consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Profit/(loss) for the period (TL) | 50.689.317 | 72.907.209 |
| Weighted average number of ordinary shares | 185.000.000 | 110.000.000 |
| Weighted average number of revised ordinary shares | 185.000.000 | 185.000.000 |
| Parent Company earnings/(loss) per share (TL) | 0,27 | 0,66 |
| Parent Company earnings/(loss) per diluted share (TL) | 0,27 | 0,39 |

* Per share of TL 1 nominal value

As 31 December 2009, the profit for the period as stated in the accompanying consolidated financial statements amounts to TL 50.689.317, and the other distributable sources amount to TL 492.672.249.

As of 31 December 2009, the net profit for the period as stated in the legal books of the Parent Company amounts to TL 39.147.689, and the other distributable sources amount to a total of TL 419.314.368.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

25. Related Party Disclosures

Trade receivables from related parties consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|--------------------------|
| Ak-Al Tekstil Sanayii A.Ş. | 4.387.694 | 6.080.848 |
| Aksu İplik Dokuma ve Boya Apre Fab. T.A.Ş.* | - | 2.593.565 |
| Akiş Gayrimenkul Yatırımı A.Ş. | 805 | 55 |
| Akport Tekirdağ Liman İşletmeleri A.Ş. | 33.029 | 34.647 |
| Akmetem Poliüretan Sanayi ve Ticaret A.Ş. | 47.600 | 10.760 |
| Ak Havacılık ve Ulaştırma Hizmetleri A.Ş. | 555 | - |
| Aksa Egypt Acrylic Fiber Industry SAE | 2.204.680 | 16.704.925 |
| Rediscount on receivables (-) | (92.958) | (197.106) |
| Total (Note 7) | <u>6.581.405</u> | <u>25.227.694</u> |

* Upon the merger realized on 1 December 2009, the indicated company has been transferred to Ak-Al Tekstil Sanayii A.Ş. with the entire amount of its assets and liabilities.

Non-trade receivables from related parties consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|--------------------------|--------------------------|
| Aksu İplik Dokuma ve Boya Apre Fab. T.A.Ş.* | - | 12.929.738 |
| Akport Tekirdağ Liman İşletmeleri A.Ş.* | 6.022.800 | - |
| Aksa Egypt Acrylic Fiber Industry SAE | 8.069 | 8.104 |
| Akmetem Poliüretan Sanayi ve Ticaret A.Ş.* | 3.505.353 | 4.609.104 |
| Akkim Kimya San. ve Tic. A.Ş. | - | 3.000 |
| Other receivables from related parties | <u>512.803</u> | <u>130.811</u> |
| Total (Note 8) | <u>10.049.025</u> | <u>17.680.757</u> |

* Includes export loan receivables utilized and transferred to group companies by the subsidiary Ak-Pa Tekstil İhracat Pazarlama A.Ş.

Short term trade payables to related parties consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|--------------------------|--------------------------|
| Akkim Kimya San. ve Tic. A.Ş. | 6.071.974 | 6.751.214 |
| Akenerji Elektrik Üretim A.Ş. | 5.626.703 | 9.055.200 |
| Akkök Sanayi Yatırım ve Geliştirme A.Ş. | 909.633 | 427.064 |
| Aktek Bilgi İletişim Teknolojisi San. ve Tic. A.Ş. | 315.360 | 250.090 |
| Dinkal Sigorta Acenteliği A.Ş. | 36.645 | 90.496 |
| Ak Havacılık ve Ulaştırma Hizmetleri A.Ş. | - | 190.767 |
| Akmetem Poliüretan Sanayi ve Ticaret A.Ş. | 147.390 | - |
| Ak-Han Bakım Yönt. Serv. Hizm. Güven. Malz. A.Ş. | 37.463 | 182.035 |
| Rediscount on payables (-) | (240.084) | - |
| Total | <u>12.905.084</u> | <u>16.946.866</u> |

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

25. Related Party Disclosures (continued)

Long term trade payables to related parties consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|-------------------------------|-------------------------|-------------------------|
| Akenerji Elektrik Üretim A.Ş. | 2.836.800 | - |
| Rediscount on payables (-) | (281.308) | - |
| Total | <u>2.555.492</u> | <u>-</u> |

Non-trade payables to related parties consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|------------------------------|-------------------------|-------------------------|
| Due to shareholders (Note 8) | <u>2.912</u> | <u>2.810</u> |

Sales to related parties for the years ended 31 December 2009 and 2008 consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---|-------------------------|-------------------------|
| Ak-Al Tekstil Sanayii A.Ş. | 24.822.751 | 28.357.307 |
| Akenerji Elektrik Üretim A.Ş. | 1.301.727 | 5.735.807 |
| Aksu İplik Dokuma ve Boya Apre Fabrikaları T.A.Ş. | 699.702 | 3.828.471 |
| Akiş Gayrimenkul Yatırımı A.Ş. | 3.516 | 33.072 |
| Ak-Han Bakım Yönt. Serv. Hizm. Güven. Malz. A.Ş. | 7.200 | 9.992 |
| Akkök Sanayi Yatırım ve Geliştirme A.Ş. | 495.469 | 466.409 |
| Akkim Kimya San. ve Tic. A.Ş. | 24.541.407 | 5.378.578 |
| Dinkal Sigorta Acenteliği A.Ş. | 23.631 | 27.632 |
| Akmerkez Lokantacılık Gıda Sanayi ve Tic. A.Ş. | - | 796 |
| Aksa Egypt Acrylic Fiber Industry S.A.E. | 37.265.070 | 38.172.074 |
| Aktek Bilgi İşlem Tekn.San.ve Tic.A.Ş. | 37.950 | 53.158 |
| Akport Tekirdağ Liman İşletmeleri A.Ş. | 77.026 | 61.664 |
| Akmetem Poliüretan Sanayi ve Ticaret A.Ş. | 39.103 | 13.225 |
| Other | <u>66.917</u> | <u>196.049</u> |
| | <u>89.381.469</u> | <u>82.334.234</u> |

Sales to related parties consist of sales of goods and services and rent income.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

25. Related Party Disclosures (continued)

Purchases from related parties for the years ended 31 December 2009 and 2008 consist of the following (TL) :

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|-------------------------|-------------------------|
| Ak-Al Tekstil Sanayii A.Ş. | 1.004.952 | 1.232.247 |
| Akenerji Elektrik Üretim A.Ş. | 52.879.606 | 94.696.931 |
| Akkök Sanayi Yatırım ve Geliştirme A.Ş. | 4.449.262 | 6.642.571 |
| Ak-Han Bakım Yönt. Serv. Hizm. Güven. Malz. A.Ş. | 552.135 | 631.591 |
| Akmetem Poliüretan Sanayi ve Ticaret A.Ş. | - | 72.003 |
| Aksu İplik Dokuma ve Boya Apre Fabrikaları T.A.Ş. | 15.120 | 104.058 |
| Dinkal Sigorta Acenteliği A.Ş. | 1.783.792 | 1.166.152 |
| Akkim Kimya San. ve Tic. A.Ş. | 58.984.998 | 66.261.525 |
| Ak Havacılık ve Ulaştırma Hizmetleri A.Ş. | 931.902 | 1.767.582 |
| Aktek Bilgi İşlem Tekn.San.ve Tic.A.Ş. | <u>4.161.514</u> | <u>2.560.945</u> |
| | <u>124.763.281</u> | <u>175.135.605</u> |

The purchases from related parties consist of energy, chemicals, service acquisitions, consultancy and rent expenses.

As of 31 December 2009, guarantees received from related parties amount to TL 2.245.680 (31 December 2008 - TL 1.478.573).

As of 31 December 2009, remuneration provided to top executives such as the CEO and members of the Board of Directors amount to TL 3.199.253 (31 December 2008 - TL 3.121.960).

26. Nature and Extent of Risk Arising from Financial Instruments

For the purpose of determining, evaluating, and managing the risks incurred by the Company, a Risk Management and Follow-up System has been developed and approved by the Board of Directors.

Finance and Risk Management meetings chaired by the General Manager are held once a month for the purpose of effective implementation of risk management at the Company. Among the participants are the Board members with executive duties and the Directors of Finance and Sales/Marketing departments. At these monthly meetings, the Company's commercial and financial risks are evaluated as well as its financial performance.

The said financial risks consist of credit risk, liquidity risk, interest rate risk, and foreign currency risk.

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

i. Credit Risk

The credit risks of the Parent Company and its Subsidiaries mainly originate from their trade receivables, other receivables, interest rate swap and forward exchange transactions. The Parent Company which has carried out its trade relations with its customers for several years has integrated in the risk management the information related to the sub-sector of the customer, rate of exports, export markets, and the history of customer's payment performance. The sales conditions on customer basis are mainly formed in the light of such information. Trade receivables risk is expected to be managed through various types of collaterals received from the customer. Such collaterals consist of bank guarantees, treasury bonds, mortgages, direct debiting system limits, letter of credit, Eximbank loan insurance, factoring limits and receiving the cheques of the clients of the customer for the purpose of risk distribution. The Company management makes provisions for doubtful receivables when deemed necessary. The Company does not foresee risks related to the Company's trade receivables in addition to the provisions made. The Parent Company has started to make foreign currency forward contracts as of 15 April 2008 for the purpose of hedging its net foreign currency assets against increase in the value of TL provided that such contracts do not exceed the limit of USD 20 million; however the application is terminated as of 23 September 2009. The foreign exchange losses to arise from such transactions are calculated taking into account the foreign currency buying rate issued by the Turkish Central Bank as of the reporting date. The other receivables of the Parent Company and its Subsidiaries mainly consist of VAT receivables. In order to realize cash reimbursement of these receivables, guarantee letters are given in favor of the tax offices.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

i. Credit Risk (continued)

The following table displays information regarding the terms overrun and warranty structure of the receivables and the cash and cash equivalents of the Parent Company and its Subsidiaries as of 31 December 2009 (TL):

| Current Period | Receivables | | | | Bank Deposits | Derivative Instruments | Other ¹ |
|---|-------------------|--------------------------|-------------------|-------------|---------------|------------------------|------------------------|
| | Trade Receivables | | Other Receivables | | | | |
| | Related Party | Other Party | Related Party | Other Party | | | |
| Maximum credit risk incurred as of 31 December 2009 (A+B+C+D+E) ² (Notes 4, 7 and 8) | 6.581.405 | 333.341.987 | 10.049.025 | 32.799.819 | 101.666.427 | - | 10.446.794 |
| - Part of maximum risk taken under guarantee through collaterals ³ | 2.245.680 | 171.700.794 | - | - | - | - | 1.952.383 |
| A. Net book value of financial assets that are neither overdue nor impaired | 6.524.550 | 316.236.949 ⁴ | 10.040.956 | 32.799.819 | 101.666.427 | - | 7.130.813 ⁴ |
| B. Book value of financial assets whose conditions are revised, and which otherwise would be considered as overdue or impaired. | - | - | - | - | - | - | - |
| - Portion taken under guarantee through collaterals | - | - | - | - | - | - | - |
| C. Net book value of overdue assets that are not impaired | 56.855 | 17.105.038 | 8.069 | - | - | - | 3.315.981 |
| - Portion taken under guarantee through collaterals | - | 12.076.380 | - | - | - | - | 689.337 |
| D. Net book values of impaired assets | - | - | - | - | - | - | - |
| - Overdue (gross book value) (Note 7) | - | 26.276.052 | - | - | - | - | - |
| - Impairment (-) (Note 7) | - | (26.276.052) | - | - | - | - | - |
| - Part of the net value taken under guarantee through collaterals | - | - | - | - | - | - | - |
| - Not overdue (gross book value) | - | - | - | - | - | - | - |
| - Impairment (-) | - | - | - | - | - | - | - |
| - Part of the net value taken under guarantee through collaterals | - | - | - | - | - | - | - |
| E. Elements involving derecognized credit risk | - | - | - | - | - | - | - |

¹ Consists of cash balances and cheques received as stated in the cash and cash equivalents.

² In determining the amount of credit risk to be incurred, factors that increase credit reliability, i.e. the guarantees received, are not taken into consideration.

³ Consists of collaterals, guarantee letters received, customer cheques and notes, treasury bonds, direct debiting system limits, Eximbank limits, factoring limits, letter of credit, and mortgages.

⁴ The cheques and notes in swap stated in trade receivables amount to TL 66.705, and the cheques and notes in swap stated as Other amount to TL 4.896.294.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

i. Credit Risk (continued)

The following table displays information regarding the terms overrun and warranty structure of the receivables and the cash and cash equivalents of the Parent Company and its Subsidiaries as of 31 December 2008 (TL):

| Current Period | Receivables | | | | Bank Deposits | Derivative Instruments | Other ¹ |
|---|-------------------|--------------------------|-------------------|-------------|---------------|------------------------|--------------------|
| | Trade Receivables | | Other Receivables | | | | |
| | Related Party | Other Party | Related Party | Other Party | | | |
| Maximum credit risk incurred as of 31 December 2008 (A+B+C+D+E) ² (Notes 4,7 and 8) | 25.227.694 | 371.536.167 | 17.680.757 | 27.676.875 | 43.545.402 | - | 20.038.153 |
| - Part of maximum risk taken under guarantee through collaterals ³ | 1.478.573 | 189.531.261 | - | - | - | - | 3.041.157 |
| A. Net book value of financial assets that are neither overdue nor impaired | 20.139.556 | 341.284.823 ⁴ | 17.671.001 | 27.676.875 | 43.545.402 | - | 1.300.314 |
| B. Book value of financial assets whose conditions are revised, and which otherwise would be considered as overdue or impaired. | - | - | - | - | - | - | - |
| - Portion taken under guarantee through collaterals | - | - | - | - | - | - | - |
| C. Net book value of overdue assets that are not impaired | 5.088.138 | 30.251.344 | 9.756 | - | - | - | 18.737.839 |
| - Portion taken under guarantee through collaterals | 32.588 | 15.125.469 | - | - | - | - | 3.041.157 |
| D. Net book values of impaired assets | - | - | - | - | - | - | - |
| - Overdue (gross book value) (Note 7) | - | 2.247.869 | - | - | - | - | - |
| - Impairment (-) (Note 7) | - | (2.247.869) | - | - | - | - | - |
| - Part of the net value taken under guarantee through collaterals | - | - | - | - | - | - | - |
| - Not overdue (gross book value) | - | - | - | - | - | - | - |
| - Impairment (-) | - | - | - | - | - | - | - |
| - Part of the net value taken under guarantee through collaterals | - | - | - | - | - | - | - |
| E. Elements involving unrecognized credit risk | - | - | - | - | - | - | - |

¹ Consists of cash balances and cheques received as stated in the cash and cash equivalents.

² In determining the amount of credit risk to be incurred, factors that increase credit reliability, i.e. the guarantees received, are not taken into consideration.

³ Consists of collaterals, guarantee letters received, customer cheques and notes, treasury bonds, direct debiting system limits, Eximbank limits, factoring limits, letter of credit, and mortgages.

⁴ The cheques and notes in swap stated in trade receivables amount to TL 42.984, and the cheques and notes in swap stated as Other amount to TL 1.165.604.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

i. Credit Risk (continued)

As of 31 December 2009, aging of assets past due but not impaired is as follows (TL):

| | <u>Receivables</u> | | <u>Other</u> |
|--|--------------------------|--------------------------|------------------------------------|
| | <u>Trade Receivables</u> | <u>Other Receivables</u> | <u>(Cash and Cash Equivalents)</u> |
| 1-30 days past due | 13.091.440* | - | 187.030 |
| 1-3 months past due | 1.872.020 | - | 1.429.818 |
| 3-12 months past due | 853.788 | - | 1.699.133 |
| 1-5 years past due | 1.344.645 | 8.069 | - |
| More than 5 years past due | - | - | - |
| Total | 17.161.893 | 8.069 | 3.315.981** |
| Portion taken under guarantee through collaterals (-) | (12.076.380) | - | (689.337) |

* A portion of TL 12.764.080 has been collected subsequent to the reporting date.

** A portion of TL 463.482 has been collected subsequent to the reporting date.

As of 31 December 2008, aging of assets past due but not impaired is as follows (TL):

| | <u>Receivables</u> | | <u>Other</u> |
|--|--------------------------|--------------------------|------------------------------------|
| | <u>Trade Receivables</u> | <u>Other Receivables</u> | <u>(Cash and Cash Equivalents)</u> |
| 1-30 days past due | 23.920.881 | - | 7.336.726 |
| 1-3 months past due | 6.059.948 | - | 11.401.113 |
| 3-12 months past due | 2.919.590 | 9.756 | - |
| 1-5 years past due | 2.439.063 | - | - |
| More than 5 years past due | - | - | - |
| Total | 35.339.482 | 9.756 | 18.737.839 |
| Portion taken under guarantee through collaterals (-) | (15.158.057) | - | (3.041.157) |

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

ii. Liquidity Risk

The Parent Company and its Subsidiaries benefit from the weekly, monthly and yearly cash flow projections they have prepared during the course of liquidity risk management. For prompt fulfillment of the liabilities of the Parent Company and its Subsidiaries, the maturity structure of the working capital is monitored in accordance with the requirements.

As of 31 December 2009, the external guarantee letters given by the Parent Company as collateral for trade payables related to raw material acquisitions amount to USD 62.829.256 (31 December 2008 - USD 54.966.596) and the guarantee letters amount to USD 55.000.000 (31 December 2008 - USD 44.472.000). As of 31 December 2009 and 2008, the guarantee letters given to customs administrations amount to TL 11.691.502 and TL 9.263.902, respectively.

As of 31 December 2009 and 2008, the Company's liquid assets (current assets - inventories) exceed its short term payables by TL 173.828.898 and TL 243.646.017, respectively.

There are no guarantees or mortgages given by the Parent Company and its Subsidiaries in favor of third parties for loans and other financial liabilities.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

ii. Liquidity Risk (continued)

As of 31 December 2009, the maturity distribution of the financial liabilities of the Parent Company and its subsidiaries are as follows (TL):

| <u>Maturities per Contract</u> | <u>Book Value</u> | <u>Total Cash Outflows as per the Contract (I+II+III+IV)</u> | <u>Less than 3 months (I)</u> | <u>3-12 months (II)</u> | <u>1-5 years (III)</u> | <u>More than 5 years (IV)</u> |
|--|-------------------|--|-------------------------------|-------------------------|------------------------|-------------------------------|
| Non-derivative financial liabilities | 347.000.570 | 356.383.235 | 170.202.039 | 42.884.901 | 143.296.295 | - |
| Bank loans (Note 6) | 279.240.701 | 287.919.455 | 101.738.259 | 42.884.901 | 143.296.295 | - |
| Trade payables (Note 7) | 67.759.869 | 68.463.780 | 68.463.780 | - | - | - |
| | | | | | | |
| <u>Expected Maturities</u> | <u>Book Value</u> | <u>Total expected cash outflows (I+II+III+IV)</u> | <u>Less than 3 months (I)</u> | <u>3-12 months (II)</u> | <u>1-5 years (III)</u> | <u>More than 5 years (IV)</u> |
| Non-derivative financial liabilities | 108.695.854 | 108.808.389 | 88.419.399 | 17.552.190 | 2.836.800 | - |
| Trade payables (Note 7) | 103.959.085 | 104.071.619 | 83.682.629 | 17.552.190 | 2.836.800 | - |
| Other payables (Note 8) | 4.736.770 | 4.736.770 | 4.736.770 | - | - | - |
| | | | | | | |
| <u>Maturities per Contract</u> | <u>Book Value</u> | <u>Total expected cash outflows (I+II+III+IV)</u> | <u>Less than 3 months (I)</u> | <u>3-12 months (II)</u> | <u>1-5 years (III)</u> | <u>More than 5 years (IV)</u> |
| Derivative financial liabilities (net) | - | (9.826.289) | (397.231) | (2.941.089) | (6.487.969) | - |
| Derivative cash inflows * | - | 1.519.963 | 171.868 | 401.916 | 946.179 | - |
| Derivative cash outflows * | - | (11.346.252) | (569.099) | (3.343.005) | (7.434.147) | - |

* The fair values of derivative operations are used in the calculation of derivative cash inflows and outflows. The six-month Libor interest rate at 31 December 2009 is taken as basis in interest swap operations.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

ii. Liquidity Risk (continued)

As of 31 December 2008, the maturity distribution of the financial liabilities of the Parent Company and its subsidiaries are as follows (TL):

| <u>Maturities per Contract</u> | <u>Book Value</u> | <u>Total Cash Outflows as per the Contract (I+II+III+IV)</u> | <u>Less than 3 months (I)</u> | <u>3-12 months (II)</u> | <u>1-5 years (III)</u> | <u>More than 5 years (IV)</u> |
|--|-------------------|--|-------------------------------|-------------------------|------------------------|-------------------------------|
| Non-derivative financial liabilities | 326.121.687 | 344.960.223 | 163.784.803 | 46.324.238 | 134.851.182 | - |
| Bank loans (Note 6) | 239.572.275 | 257.305.615 | 81.841.633 | 40.612.800 | 134.851.182 | - |
| Trade payables (Note 7) | 86.549.412 | 87.654.608 | 81.943.170 | 5.711.438 | - | - |
| <u>Expected Maturities</u> | <u>Book Value</u> | <u>Total expected cash outflows (I+II+III+IV)</u> | <u>Less than 3 months (I)</u> | <u>3-12 months (II)</u> | <u>1-5 years (III)</u> | <u>More than 5 years (IV)</u> |
| Non-derivative financial liabilities | 27.861.061 | 28.186.814 | 28.186.814 | - | - | - |
| Trade payables (Note 7) | 24.567.691 | 24.893.444 | 24.893.444 | - | - | - |
| Other payables (Note 8) | 3.293.370 | 3.293.370 | 3.293.370 | - | - | - |
| <u>Maturities per Contract</u> | <u>Book Value</u> | <u>Total expected cash outflows (I+II+III+IV)</u> | <u>Less than 3 months (I)</u> | <u>3-12 months (II)</u> | <u>1-5 years (III)</u> | <u>More than 5 years (IV)</u> |
| Derivative financial liabilities (net) | - | (10.231.435) | (1.014.732) | (3.994.595) | (5.222.108) | - |
| Derivative cash inflows * | - | 31.075.893 | 10.649.692 | 17.422.931 | 3.003.270 | - |
| Derivative cash outflows * | - | (41.307.328) | (11.664.424) | (21.417.526) | (8.225.378) | - |

* The fair values of derivative operations are used in the calculation of derivative cash inflows and outflows. The six-month Libor interest rate at 31 December 2008 is taken as basis in interest swap operations, and the foreign exchange rate of the Turkish Central Bank as of 31 December 2008 is used in forward operations.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

iii. Interest Rate Risk

Interest risk arises from the probable effect of changes in interest rates on the financial statements. Long term interest swap agreements have been made in order to avoid interest risk on long term investment loans used by the Parent Company. 6 months Libor rate is taken into account in the measurement of fair values of these transactions as of 31 December 2009. The swap operations made by the Parent Company for hedging interest risk as of 31 December 2009 and 2008 are as follows:

| Bank | Loan USD | Contract Date | Maturity | Interest Rate |
|----------------------|------------|------------------|------------------|---------------|
| Garanti Bankası A.Ş. | 18.500.000 | 2 January 2008 | 15 December 2014 | 4,18% |
| Akbank T.A.Ş. | 13.500.000 | 2 September 2008 | 15 December 2014 | 4,10% |
| Akbank T.A.Ş. | 18.000.000 | 27 March 2008 | 15 December 2014 | 3,47% |
| Fortis Bank A.Ş. | 18.970.000 | 16 April 2009 | 2 September 2014 | 2,50% |
| Fortis Bank A.Ş. | 11.100.000 | 16 April 2009 | 2 September 2014 | 2,50% |

The interest position as of 31 December 2009 and 2008 is set out in the table below (TL):

| | | <u>31 December 2009</u> | <u>31 December 2008</u> |
|--|---------------|-------------------------|-------------------------|
| Financial instruments with fixed interest | | | |
| Financial assets | Time deposits | 91.139.175 | 36.684.594 |
| Financial liabilities | Bank loans | 226.997.885 | 114.745.899 |
| | | | |
| | | <u>31 December 2009</u> | <u>31 December 2008</u> |
| Financial instruments with variable interest | | | |
| Financial liabilities | Bank loans | 51.491.142 | 124.826.376 |

As of 31 December 2009, there are no USD loans with variable interest rates (As of 31 December 2008, if the interest rates on USD loans were higher/lower by 0,5% with all other variables remaining constant, the profit/(loss) before tax would be TL 22.623 lower/higher due to change in interest expenses). In the same case, the total assets would be higher/lower by TL 633.869 as of 31 December 2009 (31 December 2008 - TL 938.450).

iv. Foreign Currency Risk

The Company's foreign currency balances arising from operating, investment and financial activities are disclosed in the table below. Foreign currency risk is monitored through continuous analysis of foreign currency receivables and payables. The net foreign currency surplus of the Parent Company and its subsidiaries as of 31 December 2009 amounts to TL 2.204.831 (31 December 2008 - TL 154.561.599 foreign currency surplus).

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

iv. Foreign Currency Risk (continued)

The foreign currency position as of 31 December 2009 and 2008 is set out in the table below:

| | 31 December 2009 | | | | | | | 31 December 2008 | | | | | |
|--|---|--------------|------------|-------|--------|-------|---------|---|-------------|------------|-------|-------|--------|
| | TL Equivalent (Functional Currency) | USD | Euro | SEK | GBP | CHF | JPY | TL Equivalent (Functional Currency) | USD | Euro | SEK | GBP | CHF |
| 1. Trade Receivables | 313.848.423 | 186.761.968 | 15.109.442 | - | - | - | - | 365.552.177 | 221.255.836 | 14.455.800 | - | - | - |
| 2a. Monetary Financial Assets (including Cash and Banks) | 64.020.265 | 41.813.828 | 484.140 | 1.751 | 6.250 | - | - | 49.713.134 | 31.838.179 | 724.093 | 1.883 | 6.272 | - |
| 2b. Non-monetary Financial Assets | 878.408 | 167.190 | 286.792 | - | - | 4.098 | - | 7.765.786 | 5.089.372 | 32.291 | - | - | - |
| 3. Other | 6.071.277 | 4.000.000 | 22.440 | - | - | - | - | 912.576 | 562.270 | 29.081 | - | - | - |
| 4. Current Assets (1+2+3) | 384.818.373 | 232.742.986 | 15.902.814 | 1.751 | 6.250 | 4.098 | - | 423.943.673 | 258.745.657 | 15.241.265 | 1.883 | 6.272 | - |
| 5. Trade Receivables | 11.741.728 | 7.791.927 | - | - | 3.944 | - | - | 13.115.765 | 8.672.727 | - | - | - | - |
| 6a. Monetary Financial Assets | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 6b. Non-monetary Financial Assets | 47.332.088 | 21.271.751 | 7.041.547 | - | 35.509 | - | 400.000 | 27.979.910 | 16.681.319 | 1.285.852 | - | - | - |
| 7. Other | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 8. Non-current Assets (5+6+7) | 59.073.816 | 29.063.678 | 7.041.547 | - | 35.509 | - | 400.000 | 41.095.675 | 25.354.046 | 1.285.852 | - | - | - |
| 9. Total Assets (4+8) | 443.892.189 | 261.806.664 | 22.944.361 | 1.751 | 45.703 | 4.098 | 400.000 | 465.039.348 | 284.099.703 | 16.527.117 | 1.883 | 6.272 | - |
| 10. Trade Payables | 136.136.011 | 85.383.616 | 3.505.948 | - | - | - | - | 88.452.490 | 58.413.541 | 53.107 | - | - | - |
| 11. Financial Liabilities | 137.556.277 | 91.357.028 | - | - | - | - | - | 100.935.398 | 66.742.973 | - | - | - | - |
| 12a. Monetary Other Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 12b. Non-Monetary Other Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 13. Short Term Liabilities (10+11+12) | 273.692.288 | 176.740.644 | 3.505.948 | - | - | - | - | 189.387.888 | 125.156.514 | 53.107 | - | - | - |
| 14. Trade Payables | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 15. Financial Liabilities | 137.400.143 | 91.253.333 | - | - | - | - | - | 121.089.861 | 80.070.000 | - | - | - | - |
| 16a. Monetary Other Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 16b. Non-Monetary Other Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 17. Long Term Liabilities (14+15+16) | 137.400.143 | 91.253.333 | - | - | - | - | - | 121.089.861 | 80.070.000 | - | - | - | - |
| 18. Total Liabilities (13+17) | 411.092.431 | 267.993.977 | 3.505.948 | - | - | - | - | 310.477.749 | 205.226.514 | 53.107 | - | - | - |
| 19. Net Asset / (Liability) Position of Derecognized Derivative Instruments in Foreign Currency (19a-19b) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 19a. Derecognized derivative instruments in foreign currency of asset type | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 19b. Derecognized derivative instruments in foreign currency of liability type | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 20. Net Foreign Currency Asset / (Liability) Position (9-18+19) | 32.799.758 | (6.187.313) | 19.438.413 | 1.751 | 45.703 | 4.098 | 400.000 | 154.561.599 | 78.873.189 | 16.474.010 | 1.883 | 6.272 | - |
| 21. Monetary Items Net Foreign Currency Asset / (Liability) Position (IFRS 7.B23) (=1+2a+5+6a-10-11-12a-14-15-16a) | (21.482.015) | (31.626.254) | 12.087.634 | 1.751 | 10.194 | - | - | 117.903.327 | 56.540.228 | 15.126.786 | 1.883 | 6.272 | - |
| 22. Total Fair Value of Financial Instruments used in Foreign Currency Hedging | - | - | - | - | - | - | - | (2.059.724) | - | - | - | - | - |
| 23. Hedged Portion of Foreign Currency Assets | - | - | - | - | - | - | - | 19.902.174 | 11.780.000 | 975.000 | - | - | - |
| 24. Hedged Portion of Foreign Currency Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 25. Exports* | 405.902.214 | 264.159.561 | - | - | - | - | - | 356.984.739 | 279.212.067 | - | - | - | - |
| 26. Imports* | 411.862.478 | 265.614.556 | 578.759 | - | - | - | - | 437.571.537 | 345.182.582 | 555.702 | - | - | 53.016 |

* Weighted average rates of exchange are taken as basis in translation of the import and export totals into Turkish Liras.

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 2008

26. Nature and Extent of Risk Arising from Financial Instruments (continued)

iv. Foreign Currency Risk (continued)

Foreign currency sensitivity analysis as of 31 December 2009 is set out in the table below (TL) :

| | <u>Profit/(Loss)</u> | | <u>Equity</u> | |
|--|---|---|---|---|
| | <u>Value increase in foreign currency</u> | <u>Value decrease in foreign currency</u> | <u>Value increase in foreign currency</u> | <u>Value decrease in foreign currency</u> |
| <u>When USD changes by 10% against TL:</u> | | | | |
| 1- Net Assets/Liabilities in USD | 8.764.476 | (8.764.476) | - | - |
| 2- Portion hedged from USD risk (-) | - | - | - | - |
| 3- USD Net Effect (1+2) | 8.764.476 | (8.764.476) | - | - |
| <u>When EURO changes by 10% against TL:</u> | | | | |
| 4- Net Assets/Liabilities in Euro | 4.199.280 | (4.199.280) | - | - |
| 5- Portion hedged from Euro risk(-) | - | - | - | - |
| 6- Euro Net Effect (4+5) | 4.199.280 | (4.199.280) | - | - |
| <u>When other currencies change by 10% against TL:</u> | | | | |
| 7- Net Assets/Liabilities in other currencies | 12.319 | (12.319) | - | - |
| 8- Part hedged from other currency risks (-) | - | - | - | - |
| 9-Net Effect of Assets in Other Currencies (7+8) | 12.319 | (12.319) | - | - |
| TOTAL (3+6+9) | 12.976.076 | (12.976.076) | - | - |

As of 31 December 2009, if the currency of the USD loans used in financing investments were to gain/lose value by 10% against the Turkish Lira with all other variables remaining constant, the total assets would be higher/lower by TL 9.696.100 due to the capitalized finance cost (31 December 2008 - TL 12.108.986).

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 200826. Nature and Extent of Risk Arising from Financial Instruments (continued)

iv. Foreign Currency Risk (continued)

Foreign currency sensitivity analysis as of 31 December 2008 is set out in the table below (TL) :

| | Profit/Loss | | Equity | |
|--|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| | Value increase in foreign currency | Value decrease in foreign currency | Value increase in foreign currency | Value decrease in foreign currency |
| <u>When USD changes by 10% against TL:</u> | | | | |
| 1- Net Assets/Liabilities in USD | 24.036.978 | (24.036.978) | - | - |
| 2- Portion hedged from USD risk (-) | (1.781.489) | 1.781.489 | - | - |
| 3- USD Net Effect (1+2) | 22.255.489 | (22.255.489) | - | - |
| <u>When EURO changes by 10% against TL:</u> | | | | |
| 4- Net Assets/Liabilities in Euro | 3.526.756 | (3.526.756) | - | - |
| 5- Portion hedged from Euro risk(-) | (208.728) | 208.728 | - | - |
| 6- Euro Net Effect (4+5) | 3.318.028 | (3.318.028) | - | - |
| <u>When other currencies change by 10% against TL:</u> | | | | |
| 7- Net Assets/Liabilities in other currencies | 1.412 | (1.412) | - | - |
| 8- Portion hedged from other currency risks (-) | - | - | - | - |
| 9-Net Effect of Assets in Other Currencies (7+8) | 1.412 | (1.412) | - | - |
| TOTAL (3+6+9) | 25.574.929 | (25.574.929) | - | - |

v. Capital Risk Management

For proper management of capital risk, the Company aims

- to maintain continuity of operations so as to provide earnings to partners and benefits to other shareholders, and
- to increase profitability through determining a service pricing policy that is commensurate with the level of risks inherent in the market.

The Company determines the amount of share capital in proportion to the risk level. The equity structure of the Company is arranged in accordance with the economic outlook and the risk attributes of assets.

The Company monitors capital management by using the debt/equity ratio. This ratio is calculated by dividing the debt, net, by the total share capital. The net debt is calculated by deducting the value of cash and cash equivalents from the total debt (the sum of short and long term liabilities stated in the statement of financial position). The total share capital is the sum of all equity items stated in the statement of financial position.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 200826. Nature and Extent of Risk Arising from Financial Instruments (continued)

v. Capital Risk Management (continued)

The Company's general strategy has not changed with respect to last year. As of 31 December 2009 and 2008, the ratios of the total share capital to total liabilities, net, are as follows (TL):

| | <u>31 December 2009</u> | <u>31 December 2008</u> |
|---------------------------------|-------------------------|-------------------------|
| Total debt | 515.317.727 | 415.273.622 |
| Less: cash and cash equivalents | <u>(112.113.221)</u> | <u>(63.583.555)</u> |
| Net debt | <u>403.204.506</u> | <u>351.690.067</u> |
| Total equity | 763.630.080 | 713.210.153 |
| Debt/Equity Ratio | 53% | 49% |

The change in the debt/equity ratio is due to the loans used by the Parent Company for its investments in progress.

27. Financial Instruments

The Parent Company and its Subsidiaries assume that the registered values of the financial instruments represent their fair values. Fair value is the amount for which a financial instrument could be exchanged between two willing parties in an arm's length transaction. It is primarily considered the same as the quoted value of the financial instrument; however in case there is no quoted value, the purchase or sales value of an instrument is deemed to be the fair value of the financial instrument. The Parent Company and its subsidiaries' significant accounting policies related to financial instruments are disclosed in paragraph (a) "Financial Instruments" of Note 2 "Presentation of Financial Statements".

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 200827. Financial Instruments (continued)

For hedging purposes against foreign currency risk, the Parent Company has made American knock out reverse participant forward transactions, and there are no forward contracts as of 31 December 2009. The current value of the outstanding forward contract as of 31 December 2008 have been calculated by referring to internal pricing models and the unrealized foreign exchange losses amounting to TL 2.059.724 (Note 13) have been recognized in the statement of comprehensive income. As of 31 December 2008, the amount, maturity, calculated expense accruals of the forward contracts are as follows:

31 December 2008;

| <u>Maturity</u> | <u>Contract Date</u> | <u>Currency</u> | <u>Foreign Currency</u> | <u>Amount</u> | <u>Calculated Expense Accrual (TL)</u> |
|-------------------------------------|----------------------|--------------------|-------------------------|-------------------------|--|
| 30 January - 30 March 2009 | 25 March 2008 | 2,1100 ≤ x | EURO | 325.000 | (30.030) |
| | | 1,7000 ≤ x ≤2,1100 | | 162.500 | |
| | | 1,7000 ≥ x | | Transaction annulled | |
| 7 January - 23 September 2009 | 13 August 2008 | 1,3400 ≤ x | USD | 310.000 | <u>(2.029.694)</u> |
| | | 1,1400 ≤ x ≤1,3400 | | 155.000 | |
| | | 1,1400 ≥ x | | Transaction annulled | |
| | | | | | <u>(2.059.724)</u> |

28. Events After the Reporting Period

The termination indemnity upper limit which stood at TL 2.365,16 as of 31 December 2009 has been increased to TL 2.427,04 with effect from 1 January 2010 (31 December 2008 - TL 2.173,19).

29. Other Issues Materially Affecting the Financial Statements or Requiring Disclosure for a Proper Interpretation and Understanding of the Financial Statements

- Insurance total on assets as of 31 December 2009 amounts to TL 37.634.280 and USD 194.877.715 (31 December 2008 - TL 24.482.948 and USD 240.746.823).
- The writing of the Parent Company dated 30 April 2009 addressed to the Istanbul Stock Exchange is as follows:

“As previously disclosed to public, the cogeneration-type facility (Yalova Plant) of 70,004-MW power established in Yalova and operating with natural gas/naphta, whose ownership belongs to Akenerji Elektrik Üretim A.Ş. by the production license dated 01.04.2005 Nr. EÜ-468- 6/529 granted by the Turkish Energy Market Regulatory Board has been transferred as per the transfer permission dated 24.10.2008 nr. 30500 of the Turkish Energy Market Regulatory Board and within the frame of the license approval decision dated 12.02.2009 nr. 4628/1157 and received by our company in its current operating condition retaining the subscribers of the existing bus bar and in a manner free of any legal or actual encumbrances.

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 200829. Other Issues Materially Affecting the Financial Statements or Requiring Disclosure for a Proper Interpretation and Understanding of the Financial Statements (continued)

b) The writing of the Parent Company dated 30 April 2009 addressed to the Istanbul Stock Exchange is as follows (continued):

The transfer fee has been determined by the parties taking as basis the Valuation Report of TSKB Gayrimenkul Değerleme A.Ş dated 29.04.2009 as TL 12.608.000,00- (Twelve million six hundred and eight thousand) plus VAT. 10% of the transfer fee amounting to TL 1.260.800,00- has been fully paid in cash on the transfer date 30.04.2009 to Akenerji Elektrik Üretim A.Ş. and the balancing portion of TL 11.347.200,00- will be paid as set out in the table below:

| <u>Maturity Date</u> | <u>Amount (TL)</u> |
|---|--------------------|
| 6 months after the transfer date of the power plant (30.04.2009) | 2.836.800 |
| 12 months after the transfer date of the power plant (30.04.2009) | 2.836.800 |
| 18 months after the transfer date of the power plant (30.04.2009) | 2.836.800 |
| 24 months after the transfer date of the power plant (30.04.2009) | <u>2.836.800</u> |
| Total | <u>11.347.200</u> |

The Turkish Energy Market Regulatory Board has granted our Company the production license dated 22.04.2009 nr. EÜ/2070-6/1464 to operate in the field of electricity generation for a period of 49 years starting on 30.04.2009 in accordance with the Electricity Market Law Nr. 4628 and the related legislation.”

c) The writing of the Parent Company dated 30 June 2009 addressed to the Istanbul Stock Exchange is as follows:

“Subject: Action Filed Against the Partnership/Progress of the Action.

| | |
|---|---|
| Filing Date | 22/06/2009 |
| Date of Notification to the Partnership/ Acknowledgement Date | 29/06/2009 |
| Title of the Action | Reversal of the decision of the Board of directors Nr. 12/06/2007/2007/32 |
| Counter party(ies) | Selahattin Tunç Cecan |
| Total amount of the Action | - |
| The ratio of the total amount of action to the total assets stated in the latest financial statements (%) | - |
| Court | 14. Commercial Court of First Instance |
| File Nr. | 2009/459 |
| Date of Hearing | 07/10/2009 |
| Court Decree | - |
| Date of Next Hearing | - |
| Provision made in the financial statements, if any | - |
| Effect on the operations of the partnership | - |

Notes to the Consolidated Financial Statements
for the years ended 31 December 2009 and 200829. Other Issues Materially Affecting the Financial Statements or Requiring Disclosure for a Proper Interpretation and Understanding of the Financial Statements (continued)

- c) The writing of the Parent Company dated 30 June 2009 addressed to the Istanbul Stock Exchange is as follows (continued):

Selahattin Tunç Cecan, a shareholder of our Company, has filed an action with the claim to determine the nullity of the decision of the Board of Directors dated 12.06.2007 nr. 2007/32 related to the sale of the shares of Akenerji Elektrik Üretim A.Ş., an enterprise owned by our Company, to Emniyet Ticaret ve Sanayi A.Ş. and Akkök Sanayi Yatırım ve Geliştirme A.Ş. due to failure to muster a quorum. The said action has been registered at the 14th Commercial Court of First Instance by File nr 2009/459 and the date / time of hearing is given as 07.10.2009 / 15:00 hrs.”

At the hearing of the said court case at the above mentioned date, decision is made to reject the court petition by reason of authorization.

- d) The writing of the Parent Company dated 10 December 2009 addressed to the Istanbul Stock Exchange is as follows:

“Subject: Action Filed Against the Partnership/Progress of the Action.

| | |
|---|---|
| Filing Date | 25/11/2009 |
| Date of Notification to the Partnership/ Acknowledgement Date | 09/12/2009 |
| Title of the Action | Claim of nullity of the decision of the Board of Directors dated 28/06/2007 nr. 2007/33 due to failure to muster a quorum |
| Counter party(ies) | Selahattin Tunç Cecan |
| Total amount of the Action | - |
| The ratio of the total amount of action to the total assets stated in the latest financial statements (%) | - |
| Court | 2nd Commercial Court of First Instance |
| File Nr. | 2009/535 |
| Date of Hearing | 03/02/2010 |
| Court Decree | - |
| Date of Next Hearing | - |
| Provision made in the financial statements, if any | - |
| Effect on the operations of the partnership | None |

Selahattin Tunç Cecan, a shareholder of our Company, has filed an action at Beyoğlu 2nd Court of First Instance with the claim to determine the nullity of the decision of the Board of Directors dated 28.06.2007 nr. 2007/33 related to the sale of the shares of Ak-Al Tekstil San. A.Ş., an enterprise owned by our Company, to Aksu İplik Dokuma ve Boya Apre Fab. T.A.Ş. due to failure to muster a quorum. The said action has been registered by File nr 2009/535 and notified to Aksa as of 09.12.2009. The date / time of hearing is given as 03.02.2010 / 14:55 hrs.”

At the hearing of the said action held on the abovementioned date, decision is made to ask for the sample registers of Aksa Akrilik Kimya Sanayi A.Ş. from Istanbul Trade Registry, and for the Resolution of the Board of Directors dated 28.06.2007 Nr. 33 from the defendant company in writing, and to allow 10 days for the defendant company to provide all means of evidence in writing. The next hearing will be held on 24.03.2010.